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Abstract——A significant challenge for neuroscien-
tists is to determine how both electrical and chemical
signals affect the activity of cells and circuits and how
the nervous system subsequently translates that activ-
ity into behavior. Remote, bidirectional manipulation
of those signals with high spatiotemporal precision is
an ideal approach to addressing that challenge. Neu-
roscientists have recently developed a diverse set of
tools that permit such experimental manipulation
with varying degrees of spatial, temporal, and direc-
tional control. These tools use light, peptides, and
small molecules to primarily activate ion channels and
G protein-coupled receptors (GPCRs) that in turn ac-
tivate or inhibit neuronal firing. By monitoring the
electrophysiological, biochemical, and behavioral ef-
fects of such activation/inhibition, researchers can
better understand the links between brain activity
and behavior. Here, we review the tools that are avail-
able for this type of experimentation. We describe the
development of the tools and highlight exciting in vivo
data. We focus primarily on designer GPCRs (recep-
tors activated solely by synthetic ligands, designer re-
ceptors exclusively activated by designer drugs) and
microbial opsins (e.g., channelrhodopsin-2, halorho-
dopsin, Volvox carteri channelrhodopsin) but also de-
scribe other novel techniques that use orthogonal re-
ceptors, caged ligands, allosteric modulators, and
other approaches. These tools differ in the direction of
their effect (activation/inhibition, hyperpolarization/
depolarization), their onset and offset kinetics (milli-
seconds/minutes/hours), the degree of spatial resolu-
tion they afford, and their invasiveness. Although
none of these tools is perfect, each has advantages and
disadvantages, which we describe, and they are all
still works in progress. We conclude with suggestions
for improving upon the existing tools.
I. Introduction
Over the past few decades, our understanding of neu-
robiology and of the links between brain function and
behavior has increased exponentially. For example, we
know now how light can be transduced from a photon
into a chemical signal that the brain can interpret (Sung
and Chuang, 2010). We understand the specific cellular
loss that contributes to Parkinson’s disease (PD1)
(Przedborski, 2005). In addition, we know how the cra-
nial nerves and descending spinal tracts stimulate the
neuromuscular junction to elicit muscle contraction and
movement. Despite these advances, knowledge of how
neuronal signals encode complex behaviors remains
vague and incomplete. Addictive drugs, for instance,
induce dopamine release in the striatum, although the
population of cells and the specific signaling pathways
within those cells that modulate drug seeking and re-
ward are incompletely identified. The brains of patients
with psychosis show evidence of decreased cortical
inhibition, but how such lowering of inhibitory in-
terneuron activity relates to the symptoms of schizo-
phrenia is unknown. In addition, we do not under-
stand, for example, how and to what extent specific
interneuron populations (e.g., parvalbumin- or calcre-
tin-expressing) might be involved in the pathogenesis
of diseases such as schizophrenia.
Elucidating the cellular and molecular substrates of
behavior remains a “grand challenge” for neuroscien-
tists and for the neuroscience field in general. In the
past, neuroscientists have administered a variety of
drugs to laboratory animals and have observed how
those drugs have subsequently affected behavior. Thus,
any conclusions regarding the links between drug ac-
tion, drug targets, and behavioral outcomes were indi-
rect and equivocal. Mouse genetic technology has per-
mitted study of loss- or gain-of-function phenotypes but
does not allow for control of receptors or pathways over
a range of activity levels, with finely tuned temporal
resolution, or for bidirectional or reversible control of
receptor activity. To conclusively define the neuronal
pathways and networks involved in behaviors—and by
extension, disruption or abnormalities of behavior—it
would be useful to have a tool that enables the direct
association between neuronal events (e.g., membrane
hyper- or depolarization, action potential firing, neu-
rotransmitter release) or activation of a specific receptor
and second-messenger-induced signaling pathway and a
behavioral outcome. In addition, such a tool should be
suitable for in vivo use in an awake, freely mobile ani-
mal. Researchers have developed a variety of techniques
that aim to achieve that goal, with varying degrees of
success. In this article, we review those tools, describing
1Abbreviations: 2-AR, 2-adrenergic receptor; 5-HT, 5-hydroxytryp-
tamine (serotonin); A3A, A3 adenosine receptor; AAV, adenoassociated
virus; ACh, acetylcholine; AlstR, allatostatin receptor; Arch, Halorubrum
sodomense archaerhodopsin-3; ATR, all-trans retinal; CA, cornu ammonis;
CaMKII, calcium/calmodulin kinase II; ChETA, channelrhodopsin-2
E123T accelerated; ChR2, channelrhodopsin-2; CNO, clozapine-n-oxide;
CNS, central nervous system; DBS, deep brain stimulation; dox, doxycy-
cline; DREADD, designer receptor exclusively activated by designer drug;
eNpHR, enhanced halorhodopsin; ER, endoplasmic reticulum; ERK, extra-
cellular signal-regulated kinase; EYFP, enhanced yellow fluorescent pro-
tein; FKBP, FK506 binding protein; floxed, flanked by loxP sites; GFAP,
glial fibrillary acidic protein; GIRK, G protein-coupled inwardly rectifying
potassium channel; GPCR, G protein-coupled receptor; h, human; hM3Dq,
human M3 muscarinic cholinergic Gq-coupled DREADD; hM4Di, human
M4 muscarinic cholinergic Gi-coupled DREADD; IRES, internal ribosomal
entry site; KOR,  opioid receptor; L-158,870, 1-(3,4-dihydroxylphenyl)-3-
methyl-1-butanone; LFP, local field potential; Mac, Leptosphaeria macu-
lans opsin; MC4, melanocortin-4; MIST, molecule for inhibition of synaptic
transmission; NpHR, Natronomonas pharaonis halorhodopsin; P, postna-
tal day (e.g., P28); PA-CNO, photoactivatable clozapine-n-oxide; PD, Par-
kinson’s disease; PIP2, phosphatidylinositol-4,5-bisphosphate; PKA, pro-
tein kinase A; PLC, phospholipase C; RASSL, receptor activated solely by
synthetic ligand; rM3/1Ds, rat M3 muscarinic/1 adrenergic Gs-coupled
DREADD; RO4, vertebrate rhodopsin 4; rtTA, reverse tetracycline trans-
activator; tet, tetracycline; THIQ, tetrahydroisoquinoline; TRE, tetracy-
cline response element; TREC, therapeutic receptor-effector complex;
TRPM, transient receptor potential melastatin; TRPV, transient receptor
potential vanilloid; tTA, tetracycline transactivator; UK-14304, 5-bromo-6-
(2-imidazolin-2-ylamino)quinoxaline; VChR1, Volvox carteri channelrho-
dopsin-1.
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their development and technical aspects as well as their
applications, with a particular focus on the central ner-
vous system (CNS). Finally, we identify persistent weak-
nesses in the currently available technology and suggest
ways to combine or improve upon the various techniques
to address those weaknesses.
II. Overview of the Tools and Their
Technical Considerations
A variety of tools is now available for remote, user-
defined control of neuronal activity. From these, two
classes of technology have emerged at the forefront of
tools for controlling neuronal signaling. First, a class of
designer GPCRs that selectively responds to small mol-
ecule ligands enables manipulation of Gq, Gi, and Gs
protein signal transduction pathways. Receptors acti-
vated solely by synthetic ligand (RASSLs) and designer
receptors exclusively activated by designer drug
(DREADDs) constitute the first and second generations,
respectively, of orthologous GPCR-ligand pairs (for re-
view, see Conklin et al., 2008; Pei et al., 2008; Nichols
and Roth, 2009; Dong et al., 2010a). Second, several
microbial light-gated receptors (opsins) functionally ex-
press in mammalian tissue and, in response to light, can
alter cell membrane potential to either hyperpolarize or
depolarize neurons and to control precisely the inten-
sity, frequency, and pattern of neuronal firing. As we
describe below, individual opsins respond to specific
wavelengths of light so that bi-directional modulation of
a single cell is feasible in an intact animal. In addition to
these two approaches to manipulating neuronal signal-
ing, several non-native or peptide receptors, such as the
TRPV1 ligand-gated ion channel and the Drosophila
melanogaster allatostatin receptor (AlstR), have suc-
cessfully provided control over neuronal activity. Ide-
ally, each of these tools would confer a high degree of
temporal, spatial, and directional control over neuronal
signaling—a goal they all achieve to varying degrees.
A. Transgenic Systems and Approaches to
Spatial Control
Spatial control enables a researcher to selectively
modulate a particular cell type (e.g., parvalbumin-ex-
pressing interneurons) or a particular anatomical region
(e.g., hippocampal CA1 pyramidal neurons). Each tool
described in this review requires expression of an exog-
enous protein or receptor, either for light (opsins) or for
small molecules (RASSLs, DREADDs, TRPV1, etc.).
Controlling either where these receptors express or the
availability of their cognate ligands (i.e., photons or
small molecules) confers the necessary spatial resolution
for defining neuronal pathways.
To date, researchers have either developed transgenic
mouse lines or have locally infused viruses with cell
type-specific promoters to achieve the necessary exoge-
nous receptor expression (Fig. 1). For both techniques,
tissue-specific promoters convey a large degree of spatial
specificity. For example, the parvalbumin, calcium/cal-
modulin kinase II (CaMKII), and glial fibrillary as-
trocytic (GFAP) promoters drive transgene expression in
basket cell interneurons, forebrain pyramidal neurons,
and astrocytes, respectively (Mayford et al., 1996; Hip-
penmeyer et al., 2005; Sweger et al., 2007). These pro-
moters can drive transgene expression directly, as in the
case of traditional transgenic mice, or indirectly through
tet-on/off or Cre-flox systems (Fig. 1). The indirect sys-
tems are advantageous because they are inducible ex-
pression systems; the tet system has some advantages in
that it is also reversible. In this latter system, a tissue-
specific promoter drives expression of a transcription
factor, either the tetracycline transactivator (tTA) or the
reverse tetracycline transactivator (rtTA) (Fig. 1A, top).
A tetracycline response element (TRE) promoter then
drives expression of the transgene of interest (Fig. 1A,
bottom). The tTA or rtTA transcription factor is required
to initiate transcription at the TRE promoter, thus the
tissue-specific promoter driving tTA or rtTA expression
determines where TRE is active. The antibiotic tetracy-
cline (tet) or its analog doxycycline (dox) regulates activ-
ity of tTA and rtTA. Tetracycline inhibits the former
transcription factor to prevent transgene expression
(tet-off; Fig. 1A, left), whereas it activates the latter
transcription factor to enable transgene expression (tet-
on; Fig. 1A, right). Expression in the tet system is
thereby reversible, in that administering or removing
tet/dox will turn expression on or off. To control the
timing of receptor expression in vivo, mice consume
either food or water that contains dox. This system is
particularly useful when exogenous receptor expression
per se induces pathologic conditions (e.g., Ro1; see sec-
tion IV.A.2), because the timing of dox administration
determines the timing and duration of receptor expres-
sion and thus controls the induction of the pathologic
condition.
The Cre-flox system functions in a similar manner,
requiring two transgenes. A tissue-specific promoter
controls expression of Cre recombinase, an enzyme from
bacteriophage that recombines DNA at specific recogni-
tion sequences termed loxP sites (Fig. 1B, top left). Cre
recombinase typically excises DNA that is flanked by
loxP sites (or “floxed”). Most often, floxed-stop constructs
are knocked-in via homologous recombination to a
housekeeping locus such as Rosa26 (Fig. 1B, bottom
left). In the presence of Cre, the stop signal is excised,
and the Rosa26 promoter drives transgene expression
(Fig. 1B, right). This technique is cell-type–specific be-
cause Cre-mediated recombination occurs only in cells
expressing Cre, which are those in which the tissue-
specific promoter is active. This system is useful in that
it is spatially regulated and inducible, but it is not re-
versible. Once recombination occurs, the user has no
control over the timing of transgene expression; the
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Rosa26 promoter will continue to drive expression of the
transgene.
Viral transgene delivery is advantageous in that it
does not require the development of a novel transgenic
mouse line and is thus less time-consuming. Virally
mediated delivery is an effective method of expressing
exogenous genes in rats and even primates—species in
which traditional transgenic approaches are unfeasible.
Viruses can directly encode the transgene of interest
downstream of a tissue-specific promoter, or they can
supply a component of the Cre-flox system. Several
groups have developed viral constructs that are now
widely used for this purpose. Alternatively called flip
excision (Schnütgen et al., 2003; Atasoy et al., 2008) or
doubly floxed, inverted open reading frame (Cardin et
al., 2009, 2010) constructs, these viruses encode a trans-
gene that is doubly floxed by variants of the canonical
loxP site so that Cre does not excise the transgene but
instead nonreversibly inverts it (Fig. 1C). The transgene
is cloned into the construct in a 3-to-5 orientation rel-
ative to the promoter (Fig. 1C, bottom left), and Cre
recombines the DNA so that the transgene is in a 5-to-3
orientation and transcription and translation of the
transgene can proceed (Fig. 1C, right). This viral con-
struct is locally infused into particular brain regions of a
Cre mouse driver line to yield tissue-specific expression.
This approach yields the same result as the traditional
Cre-flox double-transgenic approach but requires nei-
ther the development nor the maintenance of novel
transgenic lines, allows for temporal control over the
recombination process, and provides additional spatial
control as viral diffusion is limited so the location of viral
infusion contributes to the spatial resolution.
B. Temporal and Directional Control
In addition to a high degree of spatial resolution, tem-
poral resolution and directional modulation of signaling
are important characteristics of tools for remotely control-
ling neuronal signaling. Temporal control enables one to
determine when a receptor or pathway is active or inactive
and for what duration. Temporal resolution can range from
milliseconds (e.g., opsins) to minutes (e.g., TRPV1) to hours
(e.g., DREADDs) and includes both “onset” kinetics (time
between the experimental manipulation and the initiation
FIG. 1. Genetic approaches to achieving spatially regulated transgene expression. In the tet-regulated expression system (A), a tissue specific-
promoter drives expression of the tTA (tet-off, left) or rtTA (tet-on, right) transgene to produce the tTA or rtTA transcription factor, respectively, in
a driver mouse line. That line is crossed to a responsive mouse line in which the TRE promoter drives expression of the exogenous transgene of interest.
The tTA or rtTA transcription factor binds to the promoter to initiate transcription of the endogenous transgene. In the tet-off system, dox inhibits
tTA binding to the TRE promoter. In the tet-on system, doxycycline is required for rtTA binding to the promoter. In the Cre-flox system (B), a
tissue-specific promoter controls expression of Cre recombinase in a driver line. In the responsive line, loxP recognition sequences flank a stop sequence
5 of the exogenous transgene of interest. Cre recombinase excises the stop site to allow the ubiquitous Rosa26 promoter to drive transgene expression.
For virally mediated recombination (C), virus is infused into the Cre driver line. The virus carries a plasmid with a doubly floxed, inverted open reading
frame. Cre mediates recombination at one of the two sets of recognition sites to cause inversion of the open reading frame and to allow the synapsin-1
promoter to drive transgene expression in neurons. The remaining lox sites are incompatible, thereby preventing re-inversion.
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of signaling) and “offset” kinetics (time between the initi-
ation of signaling and the termination of signaling). Direc-
tional control refers to the net effect of the tool on neuronal
activity (i.e., activation versus inhibition); bidirectional
modulation is ideal. Determining the effect of both turning
on and turning off the same cell population would yield the
most information regarding the role of that cell in a par-
ticular network or behavior.
Temporal resolution is critical for directly linking ac-
tivation of particular targets or cell types to consequent
molecular, cellular, electrophysiological, and behavioral
changes. Here, we use the term “temporal resolution” to
describe the temporal characteristics of receptor activity—
how long it takes for the experimenter to effect a change
and how long those changes last. Several techniques
confer temporal control. Microbial opsins are light recep-
tors that respond rapidly (within milliseconds) to pho-
tons of a particular wavelength. Although the duration
of activity varies for each opsin, both the onset and offset
kinetics are fast relative to other techniques, as we
describe in detail below. On the other hand, DREADDs
and RASSLs respond to small-molecule ligands, signal
through G proteins, and induce responses that can
last many hours (Alexander et al., 2009). The phar-
macokinetic properties of the individual ligands and
the particular route of administration determine how
quickly neuronal signaling changes, but for systemi-
cally administered (e.g., oral administration, subcuta-
neous or intraperitoneal injection) small molecules,
responses generally begin within 5 to 15 min after
drug administration. Local administration (i.e., ste-
reotaxic infusion) of the ligand increases the temporal
resolution of the techniques requiring small molecule
ligands, but responses still occur on the order of min-
utes. Additional techniques such as using photoacti-
vatable or caged ligands yield a higher degree of tem-
poral control but that control still does not approach
that of the opsins.
Finally, directional control over system activity is im-
portant. The techniques described herein elicit neuronal
depolarization and hyperpolarization, firing, and silenc-
ing. It is beneficial to bidirectionally modulate the same
cell or population of cells to more thoroughly character-
ize the effects of activating particular pathways. Both
designer GPCRs (through Gi versus Gq or Gs signaling
partners) and opsins (through anion versus cation selec-
tivity) can inhibit and activate neuronal firing. However,
only some of these tools permit near-simultaneous bidi-
rectional manipulation of the same cells in vivo.
C. In Vivo Considerations
In this review, we focus on in vivo applications of the
techniques, which require a few special considerations
above and beyond those for an in vitro system. First, the
complexity of the nervous system and its similarity to
that of humans varies by species. Invertebrate models
(e.g., D. melanogaster, Caenorhabditis elegans) are rel-
atively simple and enable the complete dissection of
particular signaling networks, but those networks do
not necessarily translate to vertebrate nervous systems.
In contrast, vertebrate models (e.g., mice, rats) have
more in common with humans, and although it is much
more complicated to map networks in vertebrate brains,
understanding those networks is more likely to increase
knowledge of the human nervous system.
Second, genetic versatility varies by species according
to the length of gestation and mating tendencies. The D.
melanogaster, C. elegans, and Danio rerio (zebrafish)
systems are highly conducive to genetic modulation. In
fact, Zhu et al. (2009) adapted the tet-on/off system to
zebrafish. Among the vertebrate models, mice afford the
greatest degree of genetic manipulation because they
have a short gestation, and transgenic, knockin, and
knockout mice are now standard tools. To express exog-
enous genes in rats and primates, viral delivery methods
are currently necessary.
Third, the route, feasibility, and precision of local de-
livery of virus, light, and small-molecule ligands differ
across species. The larger the brain region, the easier it
is to precisely target a particular population of cells.
Thus, stereotaxic surgery is more precise in rats than in
mice, for example. In D. melanogaster, the cuticle dif-
fuses the light needed to activate the opsins, thereby
introducing an additional technical difficulty. Aerosol-
ized compounds are useful for D. melanogaster studies;
for example, scented compounds are useful as attractive
or aversive stimuli. In rodents, aversive and attractive
stimuli are distinguishable in self-administration para-
digms. In addition, metabolic processes differ across spe-
cies. For example, clozapine-n-oxide (CNO), the ligand
for DREADDs, undergoes extensive back-metabolism to
clozapine in humans (Chang et al., 1998) but not in mice
(Guettier et al., 2009). Thus, the particular animal
model determines the ideal formulation of a ligand.
Fourth, the invasiveness of the tools varies by tech-
nology. The optical approaches all require precise deliv-
ery of high-intensity light. In vertebrates, experimenters
must surgically implant fiber-optics or other devices to
deliver that light. On the other hand, the RASSL and
DREADD ligands are systemically bioavailable; thus,
their delivery is less invasive than delivery of light.
Moreover, noninvasive approaches are more conducive
to facile studies on awake, freely mobile animals, which
more reliably reflect native in vivo signaling. Thus, non-
invasive approaches are optimal, especially when con-
sidering translating these techniques to humans.
Finally, because these techniques require significant
spatial resolution, visualization of the exogenous recep-
tors is critical for verifying their localization. Fluores-
cent or epitope tags are particularly useful in vivo for the
localization of transgene expression. Epitope tags such
as hemagglutinin tags are small and generally do not
alter receptor expression, trafficking, or signaling, and
antibodies against the epitopes are readily available.
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Fluorescent tags (directly fused to the receptor) are eas-
ier to detect and can localize receptors during live imag-
ing, but these tags sometimes affect receptor trafficking
and signaling; endoplasmic reticulum (ER) export se-
quences and signal peptides improve trafficking (Zhao et
al., 2008; Dong et al., 2010a; Gradinaru et al., 2010).
Alternatively, internal ribosomal entry sequences (IRESs)
enable expression of bicistronic constructs so that the
same cells express both the receptor and the fluorescent
molecule as distinct proteins (for review, see Martínez-
Salas, 1999). This approach allows for facile identifica-
tion of cells that express the transgene but does not
inform about the level of receptor expression or the
subcellular localization of that expression. Another dis-
advantage of using IRESs is that expression of the gene
downstream of the IRES is significantly less that expres-
sion of the upstream gene (Douin et al., 2004). Although
differences in expression are permissible when the
downstream gene is merely a reporter, such differences
become problematic when the activity of the down-
stream gene is important. For example, if one wishes to
express proteins that induce opposite changes in mem-
brane potential (e.g., channelrhodopsin-2 and halorho-
dopsin; see section V) and to compare their effects on
neuronal activity, ideally they should express at equal
levels (Han et al., 2009). Conveniently, foot-and-mouth-
disease virus and other Picornaviridae express a short
sequence of 18 residues that promotes ribosomal skip-
ping between a glycine and a proline residue, resulting
in proportional translation of two separate peptides
from a single mRNA molecule (Ryan et al., 1991; Ryan
and Drew, 1994). Several groups have adapted this ap-
proach—variously termed a 2A sequence, self-cleaving
peptide, or cis-acting hydrolase element—for expression
of multiple transgenes, including distinct opsins (Tang
et al., 2009; Zimmermann et al., 2009).
Clearly, a variety of species-specific differences affect
the utility of the tools for particular applications. Thus
far, the techniques we review have been employed in
vivo in D. melanogaster, C. elegans, zebrafish, mice, rats,
and nonhuman primates.
III. Early Approaches
In one of the first attempts at “remote control” of
neuronal signaling, and, in fact, coining that phrase
(Wisden et al., 2009), Zemelman et al. (2003) used photo-
caged capsaicin and ATP to activate the TRPV1 vanil-
loid nociceptive receptor and the P2X2 purinergic recep-
tor, respectively. Since then, several other groups have
used TRPV1 (and, less notably, P2X2) to manipulate
neuronal events, as we describe below. In addition, neu-
roscientists have used caged ligands, dominant-negative
presynaptic proteins, light-gated ionotropic glutamate
receptors, and ligand-gated heterologous chloride chan-
nels, among others, to manipulate neuronal activity.
Here, we describe these techniques and some of their
advantages and shortcomings (Table 1).
A. Activation
The TRPV1 vanilloid receptor is a ligand-gated, non-
selective cation channel. TRPV1 is normally expressed
in nociceptive (pain-sensing) neurons of the peripheral
nervous system and causes membrane depolarization in
the presence of its ligand, capsaicin (Caterina et al.,
1997). Zemelman et al. (2003) first showed in cultured
hippocampal neurons that they could use light to uncage
a caged capsaicin derivative (4,5-dimethoxy-2-nitroben-
zyl-capsaicin), thereby generating action potentials in a
reliable and temporally precise manner. Depolarization
occurred approximately 5 s after a 1-s light pulse, lasted
for 2 to 3 s, and did not attenuate with multiple light
pulses. No off-target effects of the caged ligand were
evident. To our knowledge, this demonstration was the
first of precise experimental control over the on and off
kinetics of neuronal activity. Subsequently, Lima and
Miesenböck (2005) used TRPV1 and P2X2, along with
their respective photocaged ligands, to control behavior
and map neural circuits in D. melanogaster. In an ex-
treme example, they decapitated flies and successfully
made the headless bodies fly.
Arenkiel et al. (2008) subsequently used TRPV1 to
achieve remote control of neuronal signaling in verte-
brates, although they did not photocage capsaicin. Be-
cause the TRPV1 channel is not normally present in the
mouse brain, and capsaicin is highly selective for it, this
system provides high specificity. However, capsaicin ac-
tivates peripheral pain receptors and is not blood-brain-
barrier–permeant, so their approach required local infu-
sion of capsaicin via an indwelling cannula. Using the
Cre-flox system, Arenkiel et al. (2008) expressed TRPV1
throughout the brain using a nestin-Cre driver line. In
acutely prepared slices, application of capsaicin trig-
gered action potentials in TRPV1-expressing cells (iden-
tified by a bicistronic enhanced cyan fluorescent protein
reporter). In live, anesthetized mice, the authors infused
capsaicin directly into the dorsal cortex and recorded the
resultant high-frequency action potentials. The spiking
activity was dose-dependent (EC50, 500 nM) and lasted
for several seconds. Finally, they infused 500-nM capsa-
icin into awake, freely moving mice and elicited stereo-
typies between 5 and 15 min after infusion. At that
concentration, capsaicin had no damaging effects, but
doses of 5 to 10 M were excitotoxic.
Another group compared TRPV1 with its family mem-
ber TRPM8, a menthol-gated, nonselective cation chan-
nel important for sensing temperature. It is noteworthy
that Zemelman et al. (2003) had used TRPM8 in their
initial description of remote control of neuronal activity.
Crawford et al. (2009) determined that TRPM8 gener-
ated depolarizing currents similar to those of TRPV1,
but this did not result in excitotoxicity. In addition,
expression of TRPV1, but not TRPM8, altered baseline
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neurotransmission in the absence of agonist. Moreover,
prior evidence had shown that TRPV1 is endogenously
expressed in the central nervous system whereas
TRPM8 is not, which raises the possibility of additional
effects of capsaicin on neuronal firing independent of
exogenous TRPV1 (Tóth et al., 2005; Cristino et al.,
2008; Gibson et al., 2008). Therefore, Crawford et al.
(2009) reasoned that TRPM8 is a better tool than TRPV1
for activating neuronal activity.
B. Silencing
More so than neuronal activation, neuronal silenc-
ing—and reversible silencing in particular—has re-
mained a challenge to neuroscientists. Knockout and
lesion models, although in wide use, are both irrevers-
ible, and targeting particular cells is difficult or impos-
sible with those approaches. Dissatisfied with the selec-
tivity that the then-current generation of tools offered,
Lechner et al. (2002) expressed in cultured mammalian
neurons the D. melanogaster AlstR, which couples to Gi/o
to modulate GIRK channel activity and silence neuronal
activity (Birgül et al., 1999). The AlstR ligand allatosta-
tin is a short peptide that is a selective and highly potent
agonist for the D. melanogaster receptor; in addition, the
cognate ligands of related mammalian receptors (e.g.,
somatostatin and opioid receptors) are inactive at AlstR.
TABLE 1
Methods of activating and silencing neuronal activity
Tool Approach References
Activation
ChARGe Consists of D. melanogaster Arrestin, Rhodopsin, and G protein; application
of light activates rhodopsin and initiates a G protein signaling cascade
that results in action potential firing; binding of arrestin to activated
rhodopsin stops the signaling cascade; frequency and timing of action
potential firing are inconsistent and unpredictable; not feasible for in
vivo applications
Zemelman et al., 2002
FMRF-amide channel Phe-Met-Arg-Phe-amide (FMRFamide)-gated sodium channel from Helix
aspersa (HaFaNaC) is activated by FMRFamide; mammals express
homologous acid-sensing ion channels (ASICs) but not the ligand
FMRFamide; although FMRFamide activates HaFaNaC at lower
concentrations than ASICs, extent of cross-reactivity is unknown, as is
ability of endogenous mammalian amidated peptides to activate
HaFaNaC
Schanuel et al., 2008
Caged glutamate Variety of caged glutamate compounds enable neuronal activation with fast
kinetics and single-cell spatial resolution
Canepari et al., 2001;
Matsuzaki et al., 2001;
Nikolenko et al., 2007;
Fino et al., 2009
Light-gated
glutamate receptor
A photo-isomerizing glutamate molecule is covalently attached to the outer
surface of the binding pocket of an ionotropic glutamate receptor;
application of light causes isomerization, brings the glutamate into
position in the binding pocket, and opens the cation-selective channel
Volgraf et al., 2006;
Gorostiza et al., 2007;
Szobota et al., 2007;





System relies on expression of a modified glutamate- and ivermectin-gated
chloride channel from C. elegans, GluCl; point mutations reduce
sensitivity to glutamate; slow onset (4–6 h) and time to peak (12 h) of
silencing and prolonged recovery (4 days) with systemic administration;
cells must express both  and  subunits (which allows for additional
spatial resolution through intersectional expression strategies)
Li et al., 2002; Slimko et al.,
2002; Slimko and Lester,
2003; Lerchner et al.,
2007
Shibirets1 Temperature-sensitive D. melanogaster dynamin mutant gene shibirets1;
expression is induced by changes in temperature; expression causes
reversible paralysis due to depletion of synaptic vesicles at nerve
terminals; specific to D. melanogaster
Kitamoto, 2001, 2002;
Kasuya et al., 2009
Tetanus toxin light
chain
Tetanus toxin light chain TNT cleaves the synaptic vesicle protein VAMP2/
synaptobrevin; TNT expression is inducible; slow recovery (14 days)
occurs with VAMP2 resynthesis
Yamamoto et al., 2003; Yu
et al., 2004; Kobayashi et
al., 2008; Nakashiba et
al., 2008
Kir2.1 Strongly rectifying potassium channel; no cytotoxic potassium leak; channel
is constitutively active so reversibility is only achieved through
transcriptional control




Peptide neurotoxins specific for various ion channels can be tethered to the
membrane to inactivate ion channels; only reversible through
transcriptional regulation
Ibañez-Tallon et al., 2004;
Auer and Ibañez-Tallon,
2010; Auer et al., 2010;
Stürzebecher et al., 2010
5-HT1A 8-OH-DPAT is a systemically administrable ligand that selectively
activates the Gi-coupled 5-HT1A receptor to activate GIRK and
hyperpolarize neuronal membranes; requires 5-HT1A(/) background
Tsetsenis et al., 2007
GABAA-Zolpidem Positive allosteric GABAA agonists bind benzodiazepine site at interface of
 and 2 subunits; an F77I mutation of 2 abolishes zolpidem binding;
conditional expression of wild-type 2 on a 2
F77I background enables
selective neuronal silencing with zolpidem; the F77I mutation also
abolishes binding of an inverse allosteric agonist, suggesting this same
method could be used for neuronal activation
Cope et al., 2004, 2005;
Ogris et al., 2004; Wulff
et al., 2007; Wisden et al.,
2009
8-OH-DPAT, 8-hydroxy-2-dipropylaminotetralin.
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Therefore, the AlstR-allatostatin system offers desirable
two-way selectivity. Gosgnach et al. (2006) expressed
AlstR in mice in V1 motor neurons in an attempt to
dissect the role of the central pattern generator in trig-
gering locomotion. Activating AlstR-expressing neurons
in acutely prepared spinal cord slices decreased neuro-
nal excitability, whereas activating AlstR in an isolated,
intact spinal cord lengthened the electrophysiological
interval corresponding to the step-cycle period—a find-
ing that mimics the effects of developmental defects of
V1 neurons. In rats, ferrets, and monkeys expressing
AlstR, local application of high-nanomolar concentra-
tions of allatostatin inhibited both spontaneous and
evoked neuronal activity (Tan et al., 2006). Neuronal
inhibition occurred within minutes of allatostatin appli-
cation, and neurons usually recovered within minutes of
washout with saline. Moreover, allatostatin repeatedly
silenced neuronal activity without desensitization. In
addition, expression and activation of AlstR in rat neu-
rons that express glutamate and somatostatin in the
pre-Bötzinger complex, a region of the ventrolateral me-
dulla involved in respiratory drive, prevented respira-
tory movements and reduced breathing, suggesting that
these somatostatin neurons are necessary for normal
breathing rhythm (Tan et al., 2008).
These effects of allatostatin were highly specific: even
at concentrations several orders of magnitude above the
effective dose, allatostatin had no effect on wild-type
tissues. The AlstR-allatostatin system is thus selective,
reversible, and potent. The disadvantages of this system
are that allatostatin must be locally applied via invasive
techniques; its ability to reach its target (through infu-
sion and diffusion) might limit its activity; and the tem-
poral control over its activity depends on the ease of
washing in or washing out the ligand. Because allatosta-
tin is a small peptide, systemic administration in not
feasible; it would likely undergo enzymatic degradation
or would not cross the blood-brain barrier.
Also in search of an inducible and reversible method of
neuronal silencing, Karpova et al. (2005) developed
“molecules for inactivation of synaptic transmission”
(MISTs) that prevent neurotransmitter release and the
subsequent spread of action potentials. These MISTs are
modified synaptic proteins that disrupt the synaptic ves-
icle cycle when they form homo- or heterodimers in the
presence of small-molecule “dimerizers.” The authors
fused synaptic proteins (i.e., VAMP2/synaptobrevin,
synaptophysin) to FK506 binding protein (FKBP). In the
presence of an FKBP ligand, the fusion protein
dimerizes (chemical induction of dimerization) and se-
questers the presynaptic proteins, thereby inhibiting
normal neurotransmitter release. In vitro, application of
dimerizer compounds to neurons expressing MISTs
elicited a rapid decrease (50–100%) in monosynaptic
EPSPs; this inhibition was highly selective for neurons
expressing MISTs. In vivo, Karpova et al. (2005) ex-
pressed MISTs in cerebellar Purkinje neurons and then
injected dimerizer compounds into the lateral ventricles.
They found that they could selectively disrupt perfor-
mance in the Rotorod task. The inhibition lasted up to
36 h after injection and was reversible. The half-life of
the dimerizer compound in blood is approximately 5 h,
but the authors hypothesized that the compound is more
stable when bound to FKBP. Although MISTs are cer-
tainly an innovative approach for remote control of neu-
ronal signaling, the temporal control is insufficient for
many applications, and the permeability of blood-brain
barrier to the dimerizers is unknown. Whether MISTs
affect cellular processes other than neurotransmitter
release via “off-target” actions is also unknown.
The approaches described herein have their advan-
tages, but none of them permits noninvasive remote
control or achieves millisecond time scale resolution. In
addition, these systems do not enable bidirectional mod-
ulation. Therefore, two techniques have emerged in the
quest for methods of experimental manipulation of neu-
ronal signaling: orthogonal GPCR-ligand pairs and mi-
crobial opsins. The first technique provides noninvasive
control, whereas the second provides exquisite temporal
control.
IV. Designer G Protein-Coupled Receptors
G protein-coupled receptor pathways (Fig. 2) are in-
volved in a multitude of CNS disorders, and remotely
activating and/or inhibiting select GPCR pathways both
illuminates disease processes and identifies potential
avenues of treatment. Unlike microbial opsins, which
FIG. 2. Activation of second-messenger cascades by designer G pro-
tein-coupled receptors. The RASSLs and DREADDs activate Gq-, Gs-, and
Gi-coupled GPCRs. Activation of Gq activates PLC- to stimulate PIP2
hydrolysis into inositol-trisphosphate (IP3) and diacylglycerol (DAG),
then DAG activates PKC, and IP3 activates the IP3 receptor (IP3R) to
cause calcium release from the ER, which causes ERK1/2 activation.
Activation of Gs activates adenylyl cyclase (AC) to promote cAMP forma-
tion and subsequent PKA activation, whereas activation of Gi inhibits AC
activity, cAMP formation, and PKA activation. The G subunit of Gi-
coupled GPCRs opens GIRK to allow hyperpolarizing potassium flux.
Finally, G protein-independent signaling occurs through -arrestin,
which activates ERK1/2.
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are not activated in vivo by endogenous compounds or by
ambient light and thus are functionally silent at base-
line, a variety of endogenous ligands modulate native
GPCR signaling in vivo, and GPCRs can display ligand-
independent (i.e., basal, constitutive) activity (for re-
view, see, Seifert and Wenzel-Seifert, 2002; Smit et al.,
2007). Moreover, drug-like exogenous ligands are not
selective enough, and they do not provide adequate spa-
tial regulation for probing specific pathways in vivo.
Therefore, over the past 2 decades, researchers have
worked to develop highly selective orthologous ligand-
receptor pairs that would convey a high degree of spa-
tiotemporal control over GPCR signaling networks in
vivo. This work has been reviewed previously (Conklin
et al., 2008; Pei et al., 2008; Nichols and Roth, 2009;
Dong et al., 2010a).
Efforts to selectively activate GPCRs began with the
work of Strader et al. (1991) to mutagenize the 2-ad-
renergic receptor (2-AR). The Strader group identified
Asp113 as a critical residue for ligand binding to the
2-AR (Strader et al., 1987, 1988, 1989) and mutated
Asp113 to serine to interrupt ionic interactions in the
binding pocket. Although isoproterenol and the endoge-
nous agonists epinephrine and norepinephrine activated
2-AR
D113S weakly and with low potency, catechol esters
and ketones, which are inactive at the wild-type 2-AR,
were agonists at the mutant receptor. Unfortunately,
although it was a full agonist, the most potent ligand at
2-AR
D113S had an EC50 of 40 M, which is still insuf-
ficient for in vivo applications. The authors presciently
proposed rational design of drugs and genetically engi-
neered receptors as a new therapeutic approach (Strader
et al., 1991).
Since this first effort at rational design of a GPCR,
mutations to more than a dozen native GPCRs have
yielded a large family of selectively activated designer
receptors. Most of these receptors fall into two classes:
the first-generation RASSLs, which were developed
using rational design, and the second-generation
DREADDs, which were evolved through directed mo-
lecular evolution in yeast. We describe here the devel-
opment, characteristics, and applications of these two
groups of receptors.
A. First-Generation Receptors Activated Solely by
Synthetic Ligands
1. Development. After Strader’s progress, the next
advancements in the field of designer GPCRs came from
Coward et al. (1998), which took the same rational de-
sign approach as Strader et al. (1991) (i.e., mutagenizing
key residues for native ligand binding) and applied it to
the human  opioid receptor (hKOR). It is noteworthy
that peptide ligands bind to the extracellular loops,
whereas small drug-like molecules bind to transmem-
brane regions of peptide receptors. Therefore, Coward et
al. (1998) predicted it to be feasible to eliminate native
ligand binding to hKOR without decreasing the affinity
of small molecules for the receptor. Indeed, by exchang-
ing the second extracellular loop of hKOR with that of
the  opioid receptor, Coward et al. (1998) successfully
reduced the binding affinity of the endogenous peptide
dynorphin A by 200-fold (from 0.06 to 14.6 nM) yet
maintained the affinity of synthetic small molecule ago-
nists such as spiradoline and bremazocine. This novel
receptor, Ro1, faithfully couples to Gi to inhibit adenylyl
cyclase, and the potency of the native and small mole-
cule ligands parallels their respective binding affinities.
In addition, Coward et al. (1998) generated a second
RASSL (Ro2) with an E297Q mutation of Ro1. This
mutation replaces a negatively charged residue impli-
cated in ligand binding (glutamate) with a hydrophobic
residue (tryptophan) at the top of the sixth transmem-
brane region of hKOR. The affinity of several endoge-
nous opioids for Ro2 was further decreased compared
with Ro1 (e.g., the Ki of dynorphin A at Ro2 was 124.5
nM, a nearly 2000-fold decrease in affinity compared
with wild-type hKOR). Moreover, in response to spirado-
line, Ro2 induced cellular proliferation in a pertussis
toxin-sensitive manner. Although dynorphin A elicited
no detectable response in Ro2-expressing cells at concen-
trations up to 1 M, spiradoline was equipotent at
hKOR and at Ro2 (EC50, 4.4 and 5.5 nM, respectively). It
is noteworthy that the basal proliferation rate was not
different in spiradoline-treated and -untreated Ro2-ex-
pressing cells, suggesting that Ro2 does not signal con-
stitutively in this cellular context. Additional RASSLs
derived from Ro1 and Ro2 that contain fluorescent tags
or have altered internalization and/or desensitization
properties now exist (Scearce-Levie et al., 2001, 2005;
Pei et al., 2008).
The article by Coward et al. (1998)set the groundwork
for the rational design of an entire class of engineered
receptors. The authors had proposed biogenic amine—in
particular serotonin—receptors as RASSL templates
and had further suggested the benefit of developing
RASSLs that signal through each of the canonical G
protein signaling pathways. Indeed, Kristiansen et al.,
(2000) soon reported that mutation to glutamate of the
highly conserved Asp155 residue of the serotonin 2A
receptor (5-HT2A), a Gq-coupled receptor, greatly de-
creased the potency of serotonin (5-HT) but increased
the potency of gramine, a 5-HT analog that is inactive at
the native 5-HT2A receptor. In addition, the 5-HT2A
D155E
receptor had reduced basal activity compared with the
wild-type receptor. Bruysters et al. (2005) also devel-
oped a Gq-coupled RASSL that they engineered from
the H1 histamine receptor. An F435A mutation re-
duced the affinity and potency (25- and 200-fold, re-
spectively) of histamine yet increased the affinity and
potency of the synthetic phenylhistamines (54- and
2600-fold, respectively).
Srinivasan et al. (2003, 2007) developed the first
RASSLs to signal through Gs. They introduced into the
melanocortin-4 (MC4) receptor naturally occurring mu-
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tations that abolish activity of the cognate ligand -me-
lanocyte-stimulating hormone. The resulting RASSLs,
Rm1 and Rm2, are active in response to low (2–3) nano-
molar concentrations of the synthetic ligand tetrahy-
droisoquinoline (THIQ) and differ primarily in their lev-
els of basal signaling. It is noteworthy that THIQ is a
more potent agonist at the wild-type MC4 receptor than
is -melanocyte-stimulating hormone (EC50, 0.8 and
30.3 nM, respectively), so it is not selective for Rm1 or
Rm2.
Around the same time, Claeysen et al. (2003) intro-
duced into the Gs-coupled mouse 5-HT4 serotonin recep-
tor a D100A mutation that abolished the efficacy of 5-HT
at the receptor without eliminating the activity of syn-
thetic ligands. It is noteworthy that two of the synthetic
ligands that were antagonists at the wild-type receptor
were noted as agonists at the D100A receptor. In a
subsequent article, they introduced the same D100A
mutation into the human 5-HT4B serotonin receptor to
generate Rs1 (Chang et al., 2007). Like the mouse ho-
molog, this receptor was insensitive to 5-HT, but a va-
riety of synthetic ligands had full- or partial-agonist
activity, and some ligands demonstrated functional se-
lectivity (Urban et al., 2007) by directing coupling selec-
tively to Gs or jointly to Gs and Gq. Further mutations to
Rs1 or chimeras of Rs1 and the 5-HT2C or 5-HT1A sero-
tonin receptors generated receptors that differed in their
specificity of coupling to Gs, Gq, and Gi or that had
varied levels of constitutive activity. Thus, using a single
receptor template, Claeysen et al. (2003) generated a
family of RASSLs that signal through the three primary
G proteins.
In addition to these RASSLs, Pauwels and Colpaert
(2000) generated 2A-adrenergic receptors (2A-AR)
with S200A or S204A mutations. Epinephrine had
reduced potency at both mutant receptors and a 70%
decrease in efficacy at the S204A mutant, and syn-
thetic imidazoline derivatives, including 5-bromo-6-
(2-imidazolin-2-ylamino)quinoxaline (UK-14304), had
improved potency at both mutant receptors (Pauwels
and Colpaert, 2000; Pauwels, 2003). Nonetheless, the
reduction in potency of epinephrine (45- and 251-fold
for the S200A and S204A mutations, respectively) is
insufficient for in vivo selectivity.
We have described a variety of mutant receptors (cou-
pling to the Gq, Gi, and Gs signaling pathways) and
corresponding synthetic ligands that convey some level
of experimental control over cellular activity (Fig. 2).
Most of these ligand-receptor systems are useful only for
in vitro applications because of their insufficient selec-
tivity, but researchers have developed transgenic mice
expressing two of these receptors, Ro1 and Rs1.
2. In Vivo Applications. The first application of
RASSLs in an in vivo setting came from Redfern et al.
(1999), who developed transgenic mice that expressed
Ro1 in the heart under control of the -myosin heavy
chain promoter in a tet-off manner. Eleven days after
weaning adult mice from dox, 90% of atrial myocytes
and 50% of ventricular myocytes expressed Ro1. As ex-
pected on the basis of data from other Gi-coupled recep-
tors present in cardiomyocytes (e.g., M2 muscarinic, A1
adenosine), spiradoline induced a dose-dependent de-
crease in heart rate selectively in Ro1-expressing mice;
at 5 mg/kg spiradoline i.p., heart rate decreased by an
average of 55% in approximately 26 s. Thus, the onset
kinetics of spiradoline’s peripheral effects are relatively
fast. Heart rate gradually returned to near baseline
over the course of two h. In addition, Redfern et al.
(1999) showed that Ro1 desensitizes to spiradoline;
repeated injections every 4 h elicited progressively
weaker responses.
Surprisingly, once mice had been had not been receiv-
ing dox for 3 weeks, they began to die, and mortality was
virtually 100% by 16 weeks (Redfern et al., 2000). Phys-
iological and histological studies revealed that Ro1 ex-
pression per se (in the absence of agonist) induced a
lethal dilated cardiomyopathy. Ventricular conduction
delays (indicated by a wide QRS complex on electrocar-
diogram), enlarged ventricular size and decreased ven-
tricular myocardial thickness, myocyte disarray, colla-
gen deposition, reduced myocardial force and rate of
contraction/relaxation, anasarca, and labored breath-
ing—all characteristic of cardiomyopathy and/or indica-
tive of systolic dysfunction—were present only in mice
no longer receiving dox (Redfern et al., 2000; Baker et
al., 2001). It is noteworthy that a single injection of
pertussis toxin restored sinus rhythm for more than 3
days, confirming that the arrhythmias were due to Gi-
coupled signaling. In addition, mRNA microarray stud-
ies revealed changes in ventricular expression of compo-
nents of the Gi signaling pathway: GIRK gene
expression decreased by 50%, whereas expression of ad-
enylyl cyclase 7, PKA, and PKA regulatory proteins all
increased. Thus, the heart tissue seemed to be trying to
compensate for excessive Gi signaling by altering gene
expression.
These data are critical for evaluating RASSLs as an in
vivo neurobiological tool. On the one hand, the pertussis
toxin sensitivity and the alterations in expression of
genes associated with Gi signaling suggest that Ro1
signals selectively through Gi in vivo, as does hKOR.
The complete penetrance of dilated cardiomyopathy in
transgenic mice no longer receiving dox suggests, how-
ever, that Ro1 is signaling in the absence of spiradoline
or another synthetic ligand. Whether that activity indi-
cates constitutive activity or an insufficient reduction in
the efficacy and/or potency of dynorphins is unclear.
McCloskey et al. (2008) attempted to answer this ques-
tion by administering the KOR antagonist nor-binaltor-
phimine. The antagonist did not reverse the contractile
dysfunction, thus that dysfunction does not stem from
acute Ro1 signaling; it is possible, however, that the
myocardial changes are irreversible and that adminis-
300 ROGAN AND ROTH
tration of an antagonist after they develop cannot miti-
gate the accumulated effects of excess Gi signaling.
Other studies have revealed severe pathologic condi-
tions stemming from Ro1 expression; thus, the baseline
phenotype is not specific to the cardiac system. Ro1
expression in osteoblasts induces trabecular osteopenia
(Peng et al., 2008) and in astrocytes induces hydroceph-
alus (Sweger et al., 2007). For osteoblast expression, the
mouse 2.3- type 1 collagen promoter drives expression
of tTA, thus double-transgenic mice carrying both the
tTA and Ro1 transgenes express Ro1 protein selectively
in osteoblasts in a tet-off manner. Few Ro1-expressing
mice survive to weaning, and those that do survive are
severely runted, weighing less than 50% that of sex-
matched littermate control mice. Double-transgenic em-
bryos are normal and occur in Mendelian ratios. At
birth, Ro1-expressing mice have reduced mineralization
of bones and altered bone structure, and most die within
2 h from respiratory failure. In particular, trabecular
bone formation is decreased. Double-transgenic mice
that are maintained on a dox-containing diet until P28
develop reductions in trabecular bone volume after dox
has been withdrawn from the diet.
Pathologic conditions can develop from Ro1 expres-
sion in the central nervous system as well. Sweger et al.
(2007) expressed Ro1 in the tet-off system under control
of the human GFAP promoter and on a KOR(/) back-
ground. Maintenance of mice on a dox regimen elicited
no detectable phenotype, and Ro1 protein expression
was undetectable by Western blot. In the absence of dox,
Ro1 expression resulted in fatal hydrocephalus. All Ro1-
expressing mice that were never exposed to dox devel-
oped macrocephalus by P15 and severe hydrocephalus
by 12 weeks; half of the transgenic mice died by 12
weeks. If mice were exposed to dox until weaning, they
developed hydrocephalus once dox was withdrawn, indi-
cating that the phenotype is not developmentally regu-
lated. The hydrocephalus was characterized by grossly
enlarged ventricles (particularly the lateral ventricles),
reduced thickness of the cerebral cortex, disruption and
displacement of other brain structures, hemorrhage, al-
tered white tract tissue, denudation of the ependymal
lining of the lateral ventricles, and occlusion of the aq-
ueduct of Sylvius. Expression of GFAP, which indicates
reactive glia, and phosphorylated ERK, which is a down-
stream mediator of Gi signaling, both increased in Ro1-
expressing animals. These Ro1-expressing mice repre-
sent a new in vivo model of hydrocephalus. The model is
particularly useful because it occurs with 100% pen-
etrance, and it does not require administration of any
toxin or exogenous agent. In addition, one can re-
motely control the age of onset of hydrocephalus by
administering or withholding dox and thereby can
determine the role of development on hydrocephalus
and its manifestations.
Thus far, Ro1 expression in transgenic mice has not
induced a detectable baseline phenotype in only one cell
type: taste receptors. Zhao et al. (2003) used Ro1 to
investigate the sensory underpinnings of taste. They
first demonstrated that specific GPCRs in the T1R class
of taste receptors detect distinct classes of tastants
(sweet or umami). It is noteworthy that different popu-
lations of taste cells express the sweet or umami recep-
tors. To determine whether it is activation of the partic-
ular receptors for sweet/umami or whether it is the
sweet/umami receptor-expressing cells that encode
taste, Zhao et al. (2003) expressed Ro1 selectively in
sweet-sensing cells under control of a tet-on system.
Transgenic mice receiving dox, but not animals not re-
ceiving dox or wild-type animals, were attracted to spi-
radoline. In a two-bottle preference assay, Ro1-express-
ing animals preferred a spiradoline-containing solution
at concentrations as low as 10 nM; preference for the
spiradoline solution increased in a concentration-depen-
dent manner. That a nontaste receptor can elicit the
sensation of sweet taste suggests that specific pathways,
and not specific receptors, encode taste. In support of
that hypothesis, Ro1 expression in bitter taste cells of
transgenic mice induced behavioral aversion to low-
nanomolar concentrations of spiradoline (Mueller et al.,
2005). Accordingly, mice expressing a native “bitter”
receptor in sweet taste cells exhibit a strong attraction
to bitter compounds. The same receptor can convey
sweet and bitter taste, depending on where it expresses.
These studies demonstrate that taste cells, and not taste
receptors, encode the individual taste modalities (sweet,
salty, sour, bitter, umami).
Although most in vivo work with RASSLs has used
Ro1, a few studies have reported on Rs1 expression and
function in vivo. Although Ro1 expression in osteoblasts
decreases bone mass, as we described above, Rs1 expres-
sion in osteoblasts increases bone mass (Hsiao et al.,
2008, 2010a,b). Here, we have a nice example of bidirec-
tional modulation of the signaling and phenotype for the
same cell type (although activation and silencing of os-
teoblast signaling was not achieved in the same animal).
As one might expect, inhibiting and activating adenylyl
cyclase, via Gi and Gs, respectively, have opposing ef-
fects on bone structure and growth. It is noteworthy that
unlike Ro1 expression in cardiomyocytes and astrocytes,
the timing of Rs1 expression and signaling in osteoblasts
is critical for the development of pathologic conditions;
Rs1 induction after P28 does not alter trabecular bone
mass, which suggests a role for prepubertal bone growth
in osteosclerosis (Hsiao et al., 2008). Significantly, in-
duction of Rs1 expression in mice at P28, followed by
continuous or intermittent exposure to the Rs1 agonist
RS67333 from P70 to P140, greatly increased bone for-
mation (Hsiao et al., 2010b), indicating that adult bone
tissue is still sensitive to Gs-mediated signaling.
As these in vivo data show, RASSLs provide new
models of human pathologic conditions, including car-
diomyopathy, hydrocephalus, osteoporosis, and osteo-
sclerosis. These models are useful for investigating the
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signaling abnormalities that contribute to these disor-
ders, but the lack of external control over the timing or
magnitude of RASSL signaling limits their utility
for probing the signaling pathways behind complex
behaviors.
B. Second-Generation Receptors Activated Solely by
Synthetic Ligand: Designer Receptors Exclusively
Activated by Designer Drugs
Whereas the first generation of orthologous ligand-
GPCR pairs represented a significant advancement in
tools for manipulating neuronal signaling pathways,
both the in vitro and in vivo data reveal potential short-
comings of RASSLs. First, although the receptors are
activated solely by synthetic ligands, the synthetic li-
gands do not solely activate the designer receptors. For
example, spiradoline has only 200-fold higher potency at
Ro1 than at hKOR (Coward et al., 1998), and THIQ is
more potent at MC4 than at Rm1 or Rm2 (Srinivasan et
al., 2007). Therefore, to selectively activate only the
RASSL and not the native receptor in vivo, one must
either use a knockout background, which introduces a
variety of confounds into the experimental design, or one
must locally infuse the synthetic ligand to a tissue or
region that expresses only the RASSL and not the wild-
type receptor. The latter option eliminates one of the
advantages of this system (i.e., its noninvasiveness).
Second, in vivo use of RASSLs (Ro1 and Rs1) has re-
sulted in fatal baseline (in the absence of agonist) patho-
logic conditions in multiple tissues. Whether these
pathologic conditions result from constitutive activity of
RASSLs or the local concentration of endogenous ligand
is sufficient to activate RASSLs is unclear; however, the
baseline pathologic conditions stem from up-regulated
signaling of GPCR pathways.
Given these limitations of first-generation RASSLs,
we sought to develop a new generation of designer re-
ceptors that would meet all the criteria of first-genera-
tion RASSLs [i.e., no endogenous ligand would activate
the receptors, a synthetic ligand with favorable pharma-
cokinetics would activate the receptors with affinity
suitable for in vivo use (low nanomolar), and the recep-
tors would couple to each of the canonical G proteins]
with the following additional stipulations: 1) the recep-
tor would have no or minimal baseline activity; and
2) the synthetic ligand would be inert (i.e., active only at
the designer receptor and not at any endogenous target).
In this section, we summarize our progress toward this
goal.
1. Development. The first designer receptor that dis-
played two-way selectivity was actually a rationally mu-
tated 2-AR. With a goal of developing a tool suitable for
gene therapy, Small et al. (2001) developed what they
termed a therapeutic receptor-effector complex (TREC).
They mutagenized the binding pocket and several regu-
latory residues of the 2-AR and fused the C terminus of
the receptor to a modified Gs subunit. A nonbiogenic
amine [1-(3,4-dihydroxylphenyl)-3-methyl-1-butanone
(L-158,870)] that Strader et al. (1991) had originally
identified as being inactive at the wild-type 2-AR fully
activated their mutant 2-AR with low micromolar po-
tency, and endogenous 2-AR agonists were inactive at
the novel receptor. Thus, they had achieved the two-way
selectivity necessary for a TREC and a DREADD. How-
ever, they did not screen L-158,870 for activity at other
endogenous targets and, although the TREC was an
improvement upon the work from the Strader lab, the
potency of L-158,870 for the designer receptor was still
relatively low (EC50, 7 M) and not ideal for in vivo
applications.
Neoceptors and neoligands represent additional tools
with two-way selectivity (Jacobson et al., 2001, 2005,
2007; Gao et al., 2006). Neoceptors are modified adeno-
sine receptors, and their cognate ligands are modified
nucleotides. Jacobson et al. (2001, 2007) employed ratio-
nal design to generate an H272E mutation in the sev-
enth transmembrane domain of the A3 adenosine recep-
tor (A3A) that impaired affinity of native A3A ligands,
including adenosine. In addition, they added an amino
group to the ribose moiety of adenosine to yield 3-
amino-3-deoxyadenosine, a novel nucleotide with 7-fold
higher potency for A3AH272E than for wild-type A3A.
Additional adenosine derivatives yielded more selective
neoligands (Gao et al., 2006). A similar approach gener-
ated a neoceptor/neoligand pair for the A2 adenosine
receptor (A2A). The A2A neoligand has 161-fold higher
potency at the neoceptor A2AQ89D than at the wild-type
A2A (Jacobson et al., 2005). As with the TREC, neocep-
tors/neoligands were an advancement in selective mod-
ulation of a mutant receptor but were still not well
suited for in vivo use.
We took a novel approach to creating designer recep-
tors that exhibit the desired properties, namely, directed
molecular evolution (Dong et al., 2010b). Our approach
relied not on rational design—generating receptors with
deliberate mutations at residues critical for ligand bind-
ing—but instead on random mutagenesis via error-
prone polymerase chain reaction. Investigators have
successfully applied this approach to generate proteins
with specific enzymatic or catalytic activities, for in-
stance (Yuan et al., 2005). For our purposes, we first
chose a designer ligand, clozapine-n-oxide, known to be
inert at endogenous targets (Weiner et al., 2004; Arm-
bruster et al., 2007) and to be highly bioavailable and
blood-brain-barrier–permeant in both humans and mice
(Bender et al., 1994; Chang et al., 1998). Given its struc-
tural similarity to clozapine, which is a weak partial
agonist at muscarinic receptors (Davies et al., 2005), we
predicted that introducing only a few mutations to that
receptor family could yield receptors that are sensitive
to CNO (Armbruster et al., 2007). The muscarinic cho-
linergic receptor family includes five receptors: the M1,
M3, and M5 receptors couple to Gq, and the M2 and M4
receptors couple to Gi. We chose the Gq-coupled human
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M3 (hM3) muscarinic receptor, for which clozapine has
moderate affinity and weak potency, as our template
receptor; used error-prone polymerase chain reaction to
generate a library of mutants; and transformed the li-
brary into yeast. We used a strain of Saccharomyces
cerevisiae in which heterologously expressed GPCRs
couple to the pheromone signaling pathway, and activa-
tion of that pathway drives transcription and expression
of essential nutrients, thus enabling growth on selective
media (Pausch et al., 1998; Erlenbach et al., 2001; Dong
et al., 2010b). We developed three successive genera-
tions of mutant receptor libraries; we screened each for
growth in response to 10 M clozapine, 1 M CNO, or 5
nM CNO; and we selected mutants that exhibited potent
growth profiles in response to CNO but not in response
to ACh or in the absence of ligand (for a detailed proto-
col, see Armbruster et al., 2007; Dong et al., 2010b).
As predicted, introducing just two mutations rendered
hM3 insensitive to its native ligand, ACh, and highly
sensitive to the designer ligand, CNO. It is noteworthy
that these two mutations (Y149C and A239G; Fig. 3A),
which were necessary and sufficient to generate a DREADD,
were at highly conserved residues. Mutating the analo-
gous residues of other muscarinic family members gen-
erated a family of DREADDs that couple to Gi and Gq G
proteins, as do the native muscarinic receptors. In
smooth muscle cells, the Gq-coupled hM3 DREADD
(hM3Dq) potently and selectively stimulates inositol
phosphate hydrolysis (Fig. 3B), calcium release [in cul-
tured neurons as well (Alexander et al., 2009)], and
ERK1/2 activation in response to CNO, whereas the
Gi-coupled human M4 DREADD (hM4Di; derived from
the M4 muscarinic receptor) stimulates calcium release
(in a pertussis toxin-sensitive manner) and ERK1/2 ac-
tivation, inhibits forskolin-induced cAMP formation,
and, in cultured neurons, activates GIRK, thereby caus-
ing hyperpolarization and inhibition of basal action po-
tential firing (Armbruster et al., 2007). As Fig. 3B
shows, these cellular responses occur only after treat-
ment with CNO; they are notably absent after treatment
with ACh or carbachol. In addition, the receptors exhibit
no apparent baseline activity.
Because none of the native muscarinic receptors cou-
ples to Gs, Guettier et al. (2009) generated a chimera of
the rat M3 receptor in which they introduced the Y149C
and A239G mutations and exchanged the second and
third intracellular loops for those of the Gs-coupled tur-
key 1-AR (Fig. 3A). Clozapine-n-oxide maintains its
potency and efficacy at the chimeric receptor, and the
receptor couples selectively to Gs to stimulate adenylyl
cyclase, thus yielding a Gs-coupled DREADD (rM3/
1Ds) (Guettier et al., 2009). We and others have now
validated DREADDs that couple to the canonical Gq, Gi,
and Gs signaling pathways. In vitro, these receptors
have served as tools for investigating allosterism
(Nawaratne et al., 2008) and GPCR dimerization (Alva-
rez-Curto et al., 2010). Each of these receptors also func-
tions in vivo, as we describe next.
2. In Vivo Applications. For a proof-of-concept study,
we used the CaMKII promoter to drive expression of
hemagglutinin-tagged hM3Dq in the forebrain of trans-
genic mice (Alexander et al., 2009). Given the patholog-
ical baseline phenotypes that Ro1 and Rs1 induced, we
used the tet-off system so that we could control hM3Dq
expression as well as its activity. We had evolved DREADDs
to be devoid of constitutive activity, and they were in
vitro, but we did not know whether that would also hold
true in vivo. It is noteworthy that Ro1 exhibited no basal
activity in cell culture (Coward et al., 1998) but clearly
has high basal activity in vivo. Double-transgenic mice
expressed hM3Dq on the apical dendrites of cortical
pyramidal neurons and in the cell bodies and processes
of hippocampal CA1 and CA2 pyramidal neurons. Bath
application of CNO to acutely prepared brain slices de-
polarized CA1 pyramidal neurons in a PLC-dependent
manner and induced bursting-type action potential fir-
ing when tetrodotoxin was withheld from the bath. We
used multielectrode arrays to measure local field poten-
FIG. 3. DREADDs are mutant muscarinic receptors. A, DREADDs are formed by point mutations in the third and fifth transmembrane regions of
muscarinic receptors (stars; Y149C and A239G in hM3). In addition, the Gs-coupled DREADD contains the second and third intracellular loops of the
1-AR in place of those of the M3 muscarinic receptor (gray loops). B, in human pulmonary artery smooth muscle cells, the hM3Dq receptor (hM3D)
is selectively activated by CNO but not by ACh, resulting in PIP2 hydrolysis. Conversely, the wild-type M3 muscarinic receptor (hM3) is potently
activated by ACh but not by CNO. [Adapted from Armbruster BN, Li X, Pausch MH, Herlitze S, and Roth BL (2007) Evolving the lock to fit the key
to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA 104:5163–5168. Copyright © 2007
National Academy of Sciences, USA.]
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tials (LFPs) in the CA1 hippocampal region in awake,
mobile mice. We administered CNO intraperitoneally,
and LFP changes were evident within 15 min. We ob-
served a dose-dependent increase in the power of the 
band (20–100 Hz) on LFP spectrograms.  Rhythm,
which is associated with information encoding, storage,
and recall, results from synchronous, regenerative firing
of parvalbumin-expressing basket-cell interneurons. In-
deed, we observed an increase in the interneuron firing
rate during the period of  rhythm. We knew from our
slice recordings that CNO directly depolarizes pyrami-
dal cells, and we demonstrated through immunohisto-
chemical staining that hM3Dq expression is excluded
from parvalbumin-expressing cells. Thus, we reasoned
that CNO was activating glutamatergic pyramidal neu-
rons that were in turn activating interneurons (Alexan-
der et al., 2009).
We detected electrophysiological changes in double-
transgenic mice at a minimum dose of 0.1 mg/kg CNO.
At that dose, we also detected an increase in stereo-
typic behavior, and at 0.3 mg/kg CNO, hM3Dq mice
were hyperlocomotive. Doses of 0.5 mg/kg and higher
elicited behavioral and electrophysiological seizures,
status epilepticus, and death. The behavioral and
electrophysiological effects of CNO lasted for approx-
imately 10 h. However, in mice, CNO clears from
plasma within 2 h, with no back-metabolism to cloza-
pine (Guettier et al., 2009); thus, we suspect that the
long-lasting effects stem from regenerative neuronal
firing and not directly from activation of hM3Dq by
CNO.
Mice on a dox-containing diet did not respond (behav-
iorally or electrophysiologically) to CNO. Critically,
when we raised mice on a dox-free diet, we detected no
baseline pathologic condition or phenotype, indicating
that hM3Dq has no significant constitutive activity and
that an inducible expression system is unnecessary.
Therefore, floxed DREADD mice would be useful new
tools because they would allow researchers to profit from
the plethora of Cre driver lines, and no pathologic con-
dition should result from life-long DREADD expression.
This first in vivo report of DREADD function validates
its worth as a neurobiological tool.
Outside of the CNS, hM3Dq also functions in vivo.
Guettier et al. (2009) expressed either hM3Dq or rM3/
1Ds in pancreatic -cells and successfully modulated
blood glucose levels and insulin secretion with CNO.
When they administered CNO to obese, insulin-resis-
tant mice expressing hM3Dq, glucose tolerance and
-cell mass both increased.
Ferguson et al. (2011) validated hM4Di function in
vivo. They performed several proof-of-concept studies.
First, in acutely prepared slices from rats infected with
virus transducing hM4Di, application of CNO decreased
striatal neuron excitability. Specifically, CNO mediated
potassium conductance to hyperpolarize striatal neu-
rons and decrease input resistance. It is noteworthy
that no change in input resistance occurred in the
absence of CNO; no basal effect of hM4Di expression
was evident. Second, administration of CNO to rats
expressing hM4Di in the ventral tegmental area
blocked the dopamine release that normally follows a
food reward. Third, Ferguson et al. demonstrated in-
hibition with CNO of amphetamine-induced c-fos ex-
pression. Together, these studies validate the function
of hM4Di for neuronal silencing in vivo. Next, Fergu-
son et al. (2011) applied DREADD technology to the
investigation of the neurobiological activity that contrib-
utes to addiction. Using viral constructs with promoters spe-
cific for the direct and indirect striatal pathways, they ex-
pressed hM4Di in rat brains and determined the effects of
CNO on behavioral sensitization to amphetamine. They de-
termined that hM4Di-mediated silencing of direct and indi-
rect pathway neurons inhibited and facilitated behavioral
sensitization, respectively.
No published in vivo data on rM3/1Ds expression in
the brain currently exist, although we have verified the
system in vivo (M. Farrell and B. L. Roth, manuscript in
preparation). Many additional reports of DREADD use
in vivo are appearing, including the bidirectional control
of feeding behavior (Krashes et al., 2011).
V. Optical Approaches
In 2003, researchers cloned channelrhodopsin-2
(ChR2), a cation channel structurally similar to ver-
tebrate rhodopsin that opens in response to blue light
to allow Na to flow into a cell. Nagel et al. (2003)
cloned ChR2 from the green alga Chlamydomonas
reinhardtii and then demonstrated through functional
expression, both in Xenopus laevis oocytes and in
mammalian cells, that ChR2 is a directly light-gated,
cation-selective ion channel that opens rapidly upon
stimulation with light to allow cation flux. Neurosci-
entists readily appreciated the potential utility of
ChR2 as a neurobiological tool: photostimulation is a
reliable and reproducible approach to induce neuronal
spiking; upon activation of ChR2, current flows within
milliseconds; and vertebrates already express the nec-
essary cofactor, all-trans retinal (ATR), that would
enable the translation of this technology to in vivo
applications (Li et al., 2005; Herlitze and Landmesser,
2007). Indeed, in vivo studies based on activation of
ChR2 were quickly forthcoming (see Table 2). Re-
searchers also recognized that ion pumps or channels
that either depolarize or hyperpolarize neurons in
response to wavelengths of light distinct from those
that activate ChR2 would have tremendous value as
in vivo tools. Thus, several groups subsequently
sought—and identified—rhodopsin-like proteins with
those characteristics (Li et al., 2005; Han and Boyden,
2007; Zhang et al., 2007b, 2008) (Fig. 4). Below, we
describe the “optogenetic” approach that combines light-
activated receptors, or “opsins,” for temporal control with
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genetic approaches to spatial control and now constitutes
an established technique for direct depolarization and hy-
perpolarization of neurons in vivo.
A. Depolarizing Opsins
1. Channelrhodopsin-2. Boyden et al. (2005) pub-
lished the first study that used ChR2 to alter neuronal
firing. They used a lentiviral approach to express ChR2 in
cultured rat hippocampal neurons. It is noteworthy that
the receptor trafficked to the cell membrane, expression
was stable for several weeks, and expression did not alter
baseline membrane potential or resistance, which sug-
gested that ChR2 does not have basal activity and is non-
toxic to neurons. Illumination of the cultures with blue
TABLE 2
In vivo applications of optogenetics
Opsin Expression Pattern Principal Findings Reference
Mice
ChR2 Spinal neurons in and around
phrenic motor pool
Photostimulation rescues diaphragmatic respiratory
motor activity in mice with cervical spinal cord
injuries and induces plastic and adaptive changes
to enable motor activity in the absence of light
Alilain et al., 2008
Layer 2/3 pyramidal neurons
in somatosensory cortex
Mice learned to detect optical stimulation and to
make decisions based on the presence or absence
of the resultant cortical activity
Huber et al., 2008
Pyramidal cells of lateral
amygdala
Optical stimulation of lateral amygdala is sufficient
to induce fear learning; mice learned to freeze in
response to a tone that was paired with
photoactivation
Johansen et al., 2010
Dopaminergic neurons in
ventral tegmental area
Phasic stimulation was sufficient to drive
behavioral conditioning and elicited dopamine
transients
Tsai et al., 2009
Cortical interneurons Developed PINP: can use ChR2 to “tag” neurons
and monitor their activity
Lima et al., 2009
Cortical and thalamic
pyramidal neurons
Neuronal activation induces local blood oxygenation
level-dependent signals on fMRI; optogenetic
fMRI demonstrates causal effects—can visualize
and map downstream neural activity
Lee et al., 2010
Astrocytes in brainstem
chemoreceptor areas
Activating astrocytes activated the chemoreceptor
neurons in an ATP-dependent manner and
caused a respiratory response, thus
demonstrating a role of glia in a physiological
reflex
Gourine et al., 2010
Neuronal subsets throughout
brain
Mapped spatial distribution of neural circuits in
cortex
Wang et al., 2007
Hypocretin neurons Directly activating hypocretin neurons via ChR2
increased probability of awakening from slow-
wave or REM sleep
Adamantidis et al., 2007
Prefrontal cortex Stimulation of ChR2 has antidepressant-like effects
in mice previously exposed to chronic social
defeat stress
Covington et al., 2010
Central amygdala Two simultaneous papers mapped the
microcircuitry required for conditioned fear
Ciocchi et al., 2010; Haubensak
et al., 2010
Optin-receptor chimeras Nucleus accumbens Opto-1AR induced conditioned place preference,
but activation of ChR2 or opto-2AR did not
Airan et al., 2009
Drosophila
ChR2 Abnormal chemosensory jump
6 neurons
These neurons are required for startle response and
mediate escape behavior; stimulation of cells with
ChR2 elicited escape in response to light
Zimmermann et al., 2009
Olfactory receptor neurons in
larvae
Stimulation caused illusion of attractive odor with
associated crawling toward the stimulus
Bellmann et al., 2010
Subset of Rohon-Beard and
trigeminal somatosensory
neurons
Inducing a single action potential generates escape
behavior; first demonstration of electrical
activation of single cells in unrestrained
zebrafish; determined that endogenous ATR is
sufficient
Douglass et al., 2008
Zebrafish
NpHR, eNpHR, ChR2 Throughout brain Localized swim command circuitry to hindbrain
region; activating eNpHR in this region caused
larvae to stop moving and lose coordination,
while activating ChR2 elicited swimming
behavior
Arrenberg et al., 2009
NpHR, ChR2 Throughout brain Mapped eye moments that follow visual stimulus;
ChR2 activation can restore saccades in a genetic
mutant that does not normally exhibit them;
determined that saccade circuit in zebrafish is
similar to mammalian burst generator
Schoonheim et al., 2010
ChR2 Olfactory bulb, ventral
telencephalon
Adapted tet system and viral gene delivery to
zebrafish; ChR2 activation induced forward and
backward swimming
Zhu et al., 2009
PINP, photostimulation-assisted identification of neuronal populations; fMRI, functional magnetic resonance imaging; ATR, all-trans retinol.
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light (450–490 nm) induced large and rapid depolarizing
currents, whereas illumination with longer wavelengths
(490–510 nm) induced much smaller currents. Only neu-
rons expressing ChR2 responded to the light stimulus.
Continuous illumination evoked a rapid and predictable
initial spike; thereafter, no spiking pattern was evident.
Pulsed light, however, evoked reliable spike trains.
Concurrently, Li et al. (2005)used ChR2 and verte-
brate rat rhodopsin 4 (RO4)—a light-activated, Gi-cou-
pled GPCR that therefore silences neuronal firing (see
section V.C.1)—to bidirectionally modulate the electrical
activity of cultured hippocampal neurons and of intact
embryonic chick spinal cords. This study independently
replicated the results of Boyden et al. (2005), verifying
that ChR2 rapidly and reliably depolarizes neurons and
elicits action potentials. This study was also the first to
demonstrate bi-directional control of neuronal firing
with opsins. In particular, this study was important
because it showed that light penetration through tissue
does not interfere with opsin activation; light success-
fully activated opsins in intact chick embryos through a
window in the eggshell.
Simultaneously, Nagel et al. (2005) also validated
ChR2 as a tool for controlling cellular activity. They
expressed the channel in muscle cells of C. elegans,
raised the animals on an ATR-containing diet, and dem-
onstrated light-induced muscle cell contraction in the
whole animal. The contractions caused the animals to
shrink and to lay eggs, and muscles relaxed within 1 s of
the light turning off. It is noteworthy that photocurrents
did not occur in animals raised without ATR. Next,
Nagel et al. (2005) used ChR2 to depolarize mechano-
sensory neurons and elicited withdrawal reflexes in
ATR-treated animals, affirming the function of this tool
for remote control of neuronal activity in vivo.
2. Volvox carteri Channelrhodopsin-1. V. carteri ex-
presses a photosensitive, cation-conducting channelrho-
dopsin (VChR1) that responds maximally to 589-nm
light (Zhang et al., 2008). This excitation spectrum is
red-shifted from that of ChR2, most likely because of
electrostatic potential differences of the ATR-Schiff base
complex in the opsin active site (Kloppmann et al., 2005;
Zhang et al., 2008). Zhang et al. (2008) found that light
wavelengths of 406 and 589 nm are selective for ChR2
and VChR1, respectively, meaning that one could selec-
tively activate these receptors within a single neuronal
population. Another difference between the two cation
channels is that VChR1 deactivates with a decay con-
stant of 133 ms, which is notably slower than the 12 ms
that ChR2 requires; they both activate within several
milliseconds. However, the two opsins share many other
properties: they are both nonselective cation channels;
expression of neither opsin is toxic to cells or alters
membrane integrity; and supplementation with ATR is
unnecessary in mammalian neurons.
3. Channelrhodopsin-2 E123T Accelerated. Despite
its wide use, several problems with ChR2 have per-
sisted: high (and sometimes even low) levels of ChR2
expression can result in extraneous spiking in response
to a single light pulse; ChR2 cannot sufficiently drive
firing rates into the  range; and high spike rates elicit
plateau potentials. Hypothesizing that a decrease in the
deactivation time of ChR2 could resolve all three of these
problems, Gunaydin et al. (2010) used structural data
from bacteriorhodopsin to identify point mutations in
ChR2 that might accelerate the off-kinetics of channel
activity. In particular, a ChR2E123T mutant demon-
strated faster peak recovery, increased steady state-to-
peak current ratio, faster flash-to-peak current time,
and offset kinetics that were nearly twice as fast (5.2
versus 9.8 ms) as those of wild-type ChR2. The mutant,
which the authors refer to as ChETA (for ChR2 E123T
Accelerated) was functional in vitro both in cultured
hippocampal neurons and in acutely prepared brain
slices from a mouse expressing ChETA in cortical in-
terneurons. In the latter condition in response to 2-ms
light pulses, ChETA evoked neuronal spiking more reli-
ably than wild-type ChR2; each light pulse resulted in a
single action potential, even at frequencies as high as
200 Hz.
B. Hyperpolarizing Opsins
1. Halorhodopsin. The necessity of developing comple-
mentary tools to directly hyperpolarize neurons is self-
evident. Han and Boyden (2007) and Zhang et al. (2007b)
initially described the use of halorhodopsin (NpHR), a
light-activated chloride channel from Natronomonas
pharaonis that responds to yellow light (580 nm), to silence
neuronal firing. Like ChR2, NpHR silences with extremely
fast kinetics. In addition, after exposure to continuous
light, NpHR remains active for several minutes, allowing
sustained neuronal silencing. Because the wavelengths of
light that activate ChR2 and NpHR are distinct, one can
express the two receptors in the same cells to bidirection-
ally modulate their activity. Han and Boyden (2007) dem-
onstrated that alternating pulses of yellow and blue light
drive hyperpolarizations and depolarizations, respectively,
in cultured neurons expressing both ChR2 and NpHR.
FIG. 4. Activation of optical tools by distinct wavelengths of light.
Spectrum depicts the distinct wavelengths and corresponding colors of
light that maximally activate each of the various microbial opsins. Opsins
labeled in black text depolarize neuronal membranes; those labeled in
green hyperpolarize membranes; and those labeled in red couple to G
protein.
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Zhang et al. (2007b) expressed both ChR2 and NpHR in
cholinergic motor neurons or muscle cells of C. elegans and
demonstrated that NpHR activation could block ChR2-
induced muscle contraction.
One problem with ectopic NpHR expression is that
high levels of surface expression are necessary to opti-
mally silence neuronal firing, but the channel accumu-
lates in the ER (Gradinaru et al., 2008; Zhao et al.,
2008). To overcome this obstacle, Gradinaru et al. (2008)
identified an N-terminal signal peptide and a C-termi-
nal ER export sequence that increase trafficking to the
cell membrane and decrease channel retention in the
ER. Moreover, these N- and C-terminal modifications
increase the peak photocurrent that this enhanced
NpHR (eNpHR or eNpHR2.0) could generate. Further
modifications (i.e., addition of the trafficking signal from
the Kir2.1 potassium channel) to eNpHR generated
eNpHR3.0 (Gradinaru et al., 2010), which has improved
cell-membrane expression, particularly in the processes;
coincident with the improved expression are a 20-fold
increase in NpHR photocurrents and sensitivity to far-
red (630–680 nm) light. It is noteworthy that this last
improvement permits more selective activation of ChR2
and eNpHR3.0 in the same cells, albeit with moderately
(40%) reduced peak photocurrents compared with ex-
pression of only one opsin.
2. Halorubrum sodomense Archaerhodopsin-3 and
Leptosphaeria maculans Opsin. The NpHR pore is per-
meable to chloride ions, and light-activated chloride
pumps inactivate for long periods of time (tens of min-
utes). However, light-activated outward proton pumps
spontaneously reactivate within seconds. Therefore,
Chow et al. (2010) mined the plant, archaebacterial,
bacterial, and fungal opsins for light-sensitive hyperpo-
larization and identified two outward proton pumps,
archaerhodopsin-3 (Arch) from H. sodomense and Mac
from the fungus L. maculans (Waschuk et al., 2005),
that enable neuronal silencing. In response to yellow
light (peak photoactivation at 550 nm), Arch pumps
protons out of the cell within 10 ms with minimal effects
on intracellular pH, and silencing of neuronal spiking
occurs with 900 pA of current. Continuous light causes
the current to decay, and the pump rapidly inactivates
within 20 ms of the removal of light and then recovers—
all within seconds. It is noteworthy that Arch-generated
current did not saturate at high light intensities, as does
NpHR-generated current, and Arch-induced silencing
was of greater magnitude than that of NpHR; the au-
thors speculate that Arch could silence 10-fold more
brain tissue that NpHR. In vivo, Arch rapidly (with
latency near 0 ms) reduces neuronal firing, with maxi-
mal silencing of 90%. The baseline firing rate recovers
within a few hundred milliseconds. Like Arch, Mac also
hyperpolarizes neurons, but does so in response to blue-
green light, a feature that is rare among chloride pumps.
Independent silencing of distinct neuronal populations
is now possible with blue and red light. Indeed, the
authors used 630- and 470-nm light to selectively silence
NpHR- and Mac-expressing neurons, respectively.
C. G Protein-Coupled Opsins
1. Vertebrate Rhodopsin. Li et al., 2005 first used
light to activate GPCR pathways, expressing RO4 in
cultured hippocampal neurons and in intact embryonic
chick spinal cord neurons. They determined that RO4
functions both presynaptically (to inhibit voltage-gated
calcium channels and to modulate neurotransmitter re-
lease and paired-pulse facilitation) and postsynaptically
(to modulate the activity of GIRK). Therefore, RO4 al-
lows one to study G protein signaling and the effects of
neuronal silencing on a millisecond time scale. The same
group has also cloned the C-terminal tail of the Gi-
coupled 5-HT1A serotonin receptor onto RO4 (Oh et al.,
2010). The resultant chimeric protein, Rh-CT5HT1A, traf-
fics and signals like the native 5-HT1A receptor and
rescues 5-HT1A-mediated signaling in neurons or tissue
from 5-HT1A knockout mice. These data evidence the
ability of opsins to substitute for native mammalian
receptors, which should provide new opportunities for
the functional dissection of neural circuits.
2. Opsin-Receptor Chimeras. To modulate the same
intracellular biochemical pathways as GPCRs, but with
the time resolution of optical techniques, Airan et al.
(2009) created a family of opsin-GPCR fusion proteins
that are light-activated and couple to G proteins. They
exchanged the intracellular portions of rhodopsin, which
couples to Gt, with those of the 1- or 2-ARs to direct
coupling to Gq or Gs, respectively. Airan et al. (2009)
validated the selectivity of opsin-receptor chimeras for
the appropriate Gq or Gs-coupled intracellular pathways.
Whereas ligand-activated GPCRs can adopt a variety of
active conformational states, thus leading to ligand
functional selectivity (Urban et al., 2007), light-acti-
vated opsin-receptor chimeras most likely adopt a
unique conformation in response to light (Airan et al.,
2009). Hence, opsin-receptor chimeras offer less func-
tional versatility but greater temporal resolution than
designer GPCRs.
D. Advances in Light Delivery, Penetration,
and Manipulation
Optogenetics can be a technically complicated ap-
proach for in vivo manipulation of neuronal activity,
depending on the species, target tissue, and other exper-
imental variables. For example, targeting deep brain
areas (e.g., raphe nuclei) or diffuse neuronal populations
(e.g., all parvalbumin-positive neurons throughout the
forebrain) is difficult. Recently, technology for such pho-
tostimulation has greatly improved, incorporating flexi-
ble fiber optics (Aravanis et al., 2007), two-photon imag-
ing (Mohanty et al., 2008; Rickgauer and Tank, 2009;
Andrasfalvy et al., 2010), and/or improved spatial reso-
lution (Schoenenberger et al., 2008; Andrasfalvy et al.,
2010). Although a detailed description of these advances
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is beyond the scope of this review, a few advances are
highlighted here.
One problem with the basic optogenetic approach is
that single-cell activation, even in vitro, has not been
possible on an ultrafast time scale (i.e., 1 ms), in part
because ChR2 has a low channel conductance, requiring
activation of many channels to sufficiently depolarize a
neuron. With standard one-photon imaging, enough
channels are not activated with single-cell spatial reso-
lution. Two-photon imaging techniques have improved
the spatial resolution of optogenetic control of neuronal
activity, but some of the time resolution is lost because
the laser must scan a large area to activate enough
channels to cause depolarization above threshold. An-
drasfalvy et al. (2010) developed a technique, which they
refer to as temporally focused laser pulses, that enables
simultaneous excitation of many channels on single neu-
rons or in individual neuronal compartments (e.g., den-
drites, presynaptic terminals). Their approach uses mul-
tiple brief (0.1-ms) light pulses, with extremely fast
(within 0.2 ms) movement of the light focus within a
100-m field. This technique is effective in vitro on acute
brain slices.
Another challenge in optogenetics is the simultaneous
stimulation and recording of neural activity. To over-
come this challenge, some groups have glued electrodes
to the optical fibers so that both stimulation and record-
ing from the same location are possible (Gradinaru et
al., 2007), whereas others have developed and employed
“optrodes,” dual-modality devices that simultaneously
illuminate and record from neurons (Zhang et al.,
2009a). In addition, simultaneous stimulation of scat-
tered cell populations is difficult. High-intensity light-
emitting diode (i.e., LED) arrays, optical prosthetics,
and grids can provide multiple points of illumination or
illumination to deep structures (Zhang et al., 2007a;
Bernstein et al., 2008; Grossman et al., 2010). Technical
advances will undoubtedly continue to improve the in
vivo and translational applications of optogenetics.
E. In Vivo Applications
Optogenetic strategies are now widely used for in vivo
investigation of neuronal circuits and will soon become
de rigueur tools for circuitry-based dissection of neuro-
nal function. Various groups have published data on
optogenetic applications in zebrafish, D. melanogaster,
and C. elegans, and a few recent articles have described
applications in nonhuman primates (see Table 2). The
majority of the in vivo data, however, comes from ro-
dents. Table 2 describes the principal findings of many
of these in vivo studies, and we highlight below some of
the most exciting reports.
One in vivo application of optogenetics has been in PD
research. Opsins provide a method of directly testing
some of the existing hypotheses regarding the mecha-
nisms of action of various therapies. For example, in
classic basal ganglia circuitry, “direct” and “indirect”
pathway stimulation facilitates and inhibits movement,
respectively, and activating D1 receptors on direct me-
dium spiny neurons should be therapeutic. In the past,
directly activating direct pathway neurons without off-
target effects has been difficult. Moreover, high-fre-
quency deep brain stimulation (DBS) is a treatment for
refractory PD, but its therapeutic mechanism is unclear.
To investigate this circuitry, Kravitz et al. (2010) ex-
pressed ChR2 in D1 (direct) or D2 (indirect) dopamine
receptor-expressing medium spiny neurons and deter-
mined that activation of D1 neurons facilitates locomo-
tion and decreases freezing, whereas activation of D2
neurons inhibits locomotion and increases freezing be-
havior. Moreover, they showed in 6-hydroxydopamine-
lesioned mice, an animal model of PD, that activation
with light of the direct pathway completely rescues the
PD phenotype. This article was the first to directly dem-
onstrate a causal role of D1-expressing neurons in ame-
liorating PD symptoms. In addition, with the use
of 6-hydroxydopamine-lesioned mice, Gradinaru et al.
(2009) used optogenetics to dissect the various subcom-
ponents of the basal ganglia circuitry to determine the
location of action important for the therapeutic effects of
DBS. They found no positive changes in locomotor symp-
toms from either optical inhibition (via eNpHR), high-
frequency optical stimulation (via ChR2) of substantia
nigral excitatory neurons, or optical activation (via
ChR2) of substantia nigral astrocytes and subsequent
inhibition of substantia nigral neuron firing. However,
when they targeted ChR2 to afferent terminals in the
substantia nigra, high-frequency stimulation improved
PD symptoms for the duration of the stimulation. It is
noteworthy that as soon as the light pulses were discon-
tinued, locomotion immediately returned to its pre-
stimulation level, and low-frequency stimulation of the
same afferent fibers worsened PD symptoms. These
findings demonstrate well the translational potential of
optogenetics and highlight the complexity of the system
particularly with regard to the light pulse protocol.
One of the most promising translational applications
of opsins thus far is to the restoration of vision after
retinal degeneration. A variety of groups have expressed
opsins in the retina of several species (mice, rats, mar-
mosets) in photoreceptors, retinal ganglion cells, and on-
or off-bipolar cells (Lin et al., 2008; Ivanova and Pan,
2009; Tomita et al., 2009, 2010; Zhang et al., 2009b;
Busskamp et al., 2010; Ivanova et al., 2010a,b; Thyaga-
rajan et al., 2010). Busskamp et al. (2010) expressed an
eNpHR-EYFP fusion protein in photoreceptors using the
human rhodopsin, human red opsin, and mouse cone
arrestin-3 promoters. They administered eNpHR-EYFP
AAV to mice with either slow or fast forms of retinal
degeneration. Transgene expression in cone cells lasted
for more than 8 months with no evidence of toxicity.
Expression of eNpHR-EYFP and subsequent application
of light resulted in large and sustained photocurrents
that were faster than those in wild-type cones. In addi-
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tion, the cones successfully transmitted current to down-
stream ganglion cells, and spatial processing features
(e.g., lateral inhibition, directional selectivity for mo-
tion) remained intact. In light-dark box and optomotor
reflex tests, eNpHR-expressing mice performed better
than control mice, indicating that eNpHR-mediated pho-
tocurrent can modulate visually evoked behaviors and
suggesting that higher-order sensory processing re-
mains intact. Finally, Busskamp et al. (2010) treated
human ex vivo retinal explants with AAV or lentivirus,
successfully expressed eNpHR in human photorecep-
tors, and induced photocurrents and photovoltages via
eNpHR. The authors propose optogenetics as a novel
therapeutic approach to treating blind patients who re-
tain cone cell bodies in the central region of the retina.
Other groups have also attempted to rescue blindness
in animal models of retinal degeneration. Tomita et al.
(2010) expressed ChR2 in retinal ganglion cells of genet-
ically blind adult rats and observed visually evoked po-
tentials and optomotor responses, whereas Zhang et al.
(2009b) expressed NpHR or NpHR and ChR2 in inner
retinal cells in mice with retinal degeneration and re-
stored off or on-off responses, respectively.
In simultaneously published reports, Sohal et al.
(2009) and Cardin et al. (2009) employed optogenetic
strategies to investigate the molecular underpinnings of
 rhythm. Both studies used doubly-floxed, inverted
open reading frame AAV constructs to target opsins to
the forebrain. Sohal et al. (2009) expressed eNpHR-
EYFP in parvalbumin-expressing interneurons and
ChR2-EYFP in CaMKII-expressing pyramidal neurons
of the frontal cortex. Application of blue light elicited 
oscillations that were phase-locked to the flashes of blue
light, whereas yellow light inhibited, but did not elimi-
nate,  rhythm; yellow light did not affect non- LFPs.
Sohal et al. (2009) also showed in vitro in acutely pre-
pared slices that direct activation of interneurons with
ChR2 resulted in parvalbumin-interneuron firing, 
rhythm (even after nonrhythmic illumination), and in-
hibition of pyramidal neurons.
Cardin et al. (2009) targeted ChR2-mCherry to par-
valbumin-expressing interneurons or CaMKII-express-
ing pyramidal neurons in the barrel cortex of adult mice,
a region that processes sensory input from the vibrissae
(whiskers). In vivo, 1-ms light pulses to the barrel cortex
of mice with interneuron ChR2 expression induced in-
hibitory postsynaptic potentials in pyramidal cells and
inhibited the normal pyramidal response to vibrissae
deflection; the reversal potentials implicated GABAA-
mediated chloride conductance at the interneuron-pyra-
midal neuron synapse. To probe  rhythms in particular,
they stimulated at 20 to 80 Hz the barrel cortex in mice
with interneuron ChR2 expression and observed an in-
crease in the corresponding  band on the LFP. On the
other hand, an 8-Hz stimulation to mice with pyramidal
ChR2 expression increased the power of the  band on
the LFP. It is noteworthy that light-induced  rhythm
was inhibited by -amino-3-hydroxy-5-methyl-4-isoxa-
zolepropionic acid or N-methyl-D-aspartate receptor
blockade, suggesting that both the GABAergic interneu-
rons and the glutamatergic pyramidal neurons are nec-
essary to evoke  rhythms.
The studies we have summarized are just a few exam-
ples of the emerging body of literature regarding in vivo
applications of optogenetics. The rapidly growing number
of reports validates the optogenetic approach and demon-
strates that the technical aspects of photostimulation in
vivo, although challenging, are not insurmountable.
VI. Conclusions
We have described diverse approaches to experimen-
tally manipulating neuronal signaling. The approaches
rely on light, small molecules, peptides, toxins, and
other compounds to alter neuronal activity at the levels
of neurotransmitter release, membrane potential and
electrical excitability, postsynaptic receptors, and sec-
ond messenger pathways. Although each of these ap-
proaches has its advantages and disadvantages (some of
which we discuss below), the techniques are largely com-
plementary. Ideally, researchers will soon begin to com-
bine multiple approaches to modulating signaling to de-
termine the interplay between the targeted pathways.
A. Advantages and Disadvantages of the Approaches
1. Designer G Protein-Coupled Receptors. The
RASSLs and DREADDs, unlike most of the other tech-
niques, directly target G protein signaling pathways and
are likely to have extraordinarily diverse effects. These
effects range from altering membrane excitability (e.g.,
G-mediated opening of GIRK, Gq-mediated closing of
PIP2-gated KCNQ channels) to inducing gene expres-
sion (e.g., Gq induction of c-fos expression). On the one
hand, such a broad spectrum of effects sometimes ob-
scures the precise mechanisms underlying altered neu-
ronal activity. On the other hand, most of the intracel-
lular signaling pathways are well defined, and the
induction of such varied effects increases the versatility
of this tool.
Direct, noninvasive remote control of GPCR activity is
particularly important for translational applications.
The majority of drugs approved by the U.S. Food and
Drug Administration act through GPCRs, and most pre-
scribed drugs are available as oral formulations. Be-
cause many of these techniques for controlling neuronal
signaling have as a long-term goal clinical use in hu-
mans, in general designer GPCRs are perhaps the most
feasible as therapeutics (except for certain treatments,
such as DBS).
One undefined aspect of DREADD/RASSL function is
their ability to signal via G protein-independent mech-
anisms (i.e., -arrestin). As researchers gain an under-
standing of the importance of -arrestinergic signaling,
functional selectivity becomes particularly relevant (Ur-
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ban et al., 2007). Functional selectivity refers to both the
ability of a ligand, acting at a given receptor, to prefer-
entially activate different intracellular signal transduc-
tion pathways (biased agonism) and more broadly, the
ability of a ligand, acting at a given receptor, to have
different effects depending on the cell type and available
intracellular signaling machinery. For example, both
Chang et al. (1998) and Claeysen et al. (2003) described
functional selectivity of 5-HT4
D100A receptor ligands.
The latter reported that ligands could be antagonists at
the wild-type 5-HT4 receptor but agonists at the D100A
receptor, whereas the former group reported that vari-
ous ligands could couple directly only to Gs or to both Gs
and Gq signaling pathways.
Indeed, designer GPCRs provide an ideal method of
investigating such differential signaling. First, we can
express them in distinct tissues or cell types to deter-
mine how activating the same G protein can have dif-
ferent effects, depending on its signaling partners. For
example, we hypothesized that the underlying mecha-
nism of CNO-induced seizures in mice expressing
hM3Dq in the hippocampus is reduced stability of the
membrane potential as a result of activation of the Gq-
PLC-PIP2 hydrolysis pathway and subsequent closing
of PIP2-gated KCNQ outwardly rectifying potassium
channels (Alexander et al., 2009). In other neuronal
populations or even subcellular compartments that do
not express KCNQ channels, however, activation of the
same Gq-PLC-PIP2 hydrolysis pathway might effect
different alterations in neuronal function. Thus, we
should continue to express these receptors in diverse cell
types to determine the differential roles of G protein-
mediated signaling.
Furthermore, native GPCRs express in distinct sub-
cellular compartments, and their downstream effects
depend on local signaling machinery and scaffolds. The
postsynaptic density is a nice example of a subcellular
compartment that mediates signaling of postsynaptic
receptors. Using trafficking signals and signal peptides
similar to those already in use for optogenetics (Gradi-
naru et al., 2007; Gradinaru et al., 2010), we are cur-
rently targeting DREADDs to specific subcellular com-
partments to modulate different intracellular pathways
and to improve our ability to study functional selectivity
(Dong et al., 2010a). Developing such tools would
greatly further our ability to remotely modulate neu-
ronal signaling.
Returning to -arrestinergic signaling, we do not
know the extent to which mutant GPCRs mimic the
signaling properties of their wild-type templates. With
regard to rM3/1Ds in particular, it would be interesting
to know the extent to which it signals through -arrestin
because the -arrestinergic signaling properties of the
-adrenergic receptors are so well defined, and the sec-
ond and third intracellular loops of rM3/1Ds are those
of the 1-AR. Work is under way in our lab to answer
this question. Then, we hope to develop CNO analogs or
additional DREADD ligands that exhibit a range of ef-
ficacies for both G protein-dependent and -independent
signaling. In addition, we can generate DREADDs with
mutations or deletions of their intracellular loops that
affect their ability to signal via these two mechanisms.
Such avenues of research are particularly important
given a recent report that the clinical efficacy of antipsy-
chotic drug action might depend on G protein-indepen-
dent signaling and that ligands that show a bias toward
-arrestinergic signaling might have high potential as
antipsychotic treatments (Masri et al., 2008).
With regard to additional DREADD ligands, one dis-
advantage of second-generation designer GPCRs is that
thus far, CNO is their only agonist. Therefore, one can-
not express multiple DREADDs (e.g., hM3Dq and
hM4Di) in the same cell or animal to bidirectionally
modulate the same pathways, as is possible with opto-
genetics. On the other hand, first-generation designer
receptors (RASSLs) are based on multiple native recep-
tors, so different ligands activate the receptors; thus, the
same mouse can express, for example, Rs1 and Ro1 in
the same cell populations. With a bit of luck, other
DREADDs that respond to novel ligands will soon be
available to allow such bidirectional modulation within
the same animal.
Another problematic aspect of DREADDs is that
whereas CNO is an ideal ligand in mice—it is orally
bioavailable, blood-brain-barrier–permeant, and does
not undergo back-metabolism to clozapine, which has
activity at more than 50 neuronal targets—back-metab-
olism in humans is significant and would prevent the
transfer of DREADD technology to humans. Therefore, a
nonmetabolized CNO derivative or a novel DREADD
ligand is required before DREADDs can move into high-
er-order animals for preclinical testing. Alternatively,
CNO analogs with altered pharmacokinetics (i.e., biodis-
tribution) might permit the translation of DREADD
technology to human therapeutics.
Finally, and probably the biggest drawback of de-
signer GPCRs, particularly in comparison with opsins, is
the time resolution they afford. Designer GPCRs activate
over the course of tens of minutes. Many of the ligands are
orally bioavailable and can penetrate the blood-brain
barrier, their use thus enabling noninvasive remote con-
trol of neuronal signaling. Some users have directly in-
fused the ligands into the brain, thereby reducing the
time required to activate the receptors and further in-
creasing the spatial resolution of the technology, but the
time resolution still does not approach that of the opsins,
and the benefit of a noninvasive approach is lost. An-
other method of improving the time resolution of CNO,
for example, would be to develop a photoactivatable
CNO derivative (PA-CNO). One could then treat a live
animal with PA-CNO, allow enough time for absorption
and distribution, and then use focal light to activate
CNO in particular brain regions. This approach would
increase both the time and spatial resolution of designer
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GPCR technology. However, PA-CNO would no longer
provide a noninvasive or nontechnical method of control-
ling neuronal signaling because an invasive approach
would be necessary to introduce the light stimulus nec-
essary to activate the PA-CNO.
On the one hand, GPCRs will never permit the time
resolution of opsins. On the other hand, they might not
need to. Signaling through GPCRs is notably slower
than that through ion channels, but is no less important
for normal cellular function. Although ion channels
serve to rapidly transmit encoded information, GPCRs
serve to amplify and diversify that transmission. There-
fore, these two tools truly are complementary and
equally valuable. Moreover, as we mentioned previously,
most approved drugs act through GPCRs, so altering
cellular function over a longer period clearly can be
therapeutic.
2. Opsins. The numerous advantages of optogenetics
are evident from the plethora of in vivo studies already
reported in multiple species (see Table 2). Optogenetics,
more than any other technology reviewed in this article,
enables ultrafast millisecond time scale dissection of
neural circuitry. Only optical approaches can replicate
the kind of endogenous oscillatory activity seen in neu-
rons. Although this ability is paramount for high-fre-
quency DBS to alleviate PD symptoms (Gradinaru et al.,
2009), whether such a high degree of temporal control is
necessary for other applications is unclear. For example,
some endogenous substances (e.g., hormones) travel a
significant distance from their site of synthesis and re-
lease to their site of action, where they alter transcrip-
tion. Extreme temporal precision with regard to such
pathways is likely unnecessary.
Another advantage of the optical approaches is that
they act via a simple mechanism: opening of a channel or
pump to allow ion flow. In contrast to GPCRs, which
directly activate G, G, and -arrestin, each with its
own downstream effects, altering ion flow and therefore
membrane potential is the only direct action of opsins.
This well defined mechanism of action simplifies data
interpretation and analysis. Some intracellular sig-
naling pathways are accessible through vertebrate
rhodopsin, melanopsin (Lin et al., 2008), and the op-
sin-receptor chimeras, but these approaches are un-
likely to enable investigations into biased agonism or
other forms of functional selectivity.
Finally, the optogenetic approach is the most specific.
In mammals, the only light-sensitive endogenous recep-
tors are in the retina, so photostimulation of the brain
induces only opsin-mediated effects. Moreover, although
light scatters as it penetrates tissue, there are no phar-
macokinetic concerns with light as a ligand as there are
for CNO and other metabolized compounds. In addition,
some of the newer technical developments enable illu-
mination of individual neuronal compartments (e.g.,
dendrites), providing an incredible degree of spatial res-
olution. With DREADDs/RASSLs, such spatial resolu-
tion is possible only through photocaging of ligands or
through targeting of receptor expression to those com-
partments. In the latter case, activation of individual
neurons is possible but technically challenging.
Photostimulation presents a few challenges, particu-
larly in conjunction with recording of electrical activity.
First, light that is too strong or is applied for too long can
cause tissue damage, abnormal neuronal activity, and
excitotoxicity (Cardin et al., 2010). One can minimize
these effects by using lower light intensity or shorter
pulses instead of continuous illumination, but between
the light scatter and minimizing the light intensity, it
might be difficult to sufficiently target deep brain struc-
tures without using a stereotaxic approach to photo-
stimulation. In addition, high levels of opsin expression
are typically necessary to generate sufficient current;
trafficking signals and other modifications improve sur-
face expression and even maximal current flow to lessen
this problem. Finally, electrical artifacts are common
sequelae of the light source illuminating metal recording
electrodes. In a recent protocol article, Cardin et al.
(2010) describe several approaches to minimizing such
artifacts, including using opaque glass electrodes, min-
imizing exposed metal, and using thin wire stereotrodes
adjusted so that minimal light directly reaches them.
B. Combining the Systems
No one has yet combined optical and GPCR-based
approaches to remote control of neuronal signaling.
Such combinations of approaches would answer some of
the questions about whether the precise timing and pat-
tern of electrical activity or the intracellular second-
messenger pathways are more important in certain con-
texts. The role of  rhythm in cortical inhibition and
psychosis presents a nice example of how these tech-
niques can work together, because both hM3Dq and
ChR2 can stimulate  rhythm (Alexander et al., 2009;
Cardin et al., 2009; Sohal et al., 2009). It would be
interesting to use the viral self-cleaving 2A peptide se-
quence to equally express both hM3Dq and ChR2 or
hM4Di and eNpHR under the parvalbumin or CaMKII
promoters and to compare the effects of electrical versus
pharmacological stimulation and inhibition of each cell
type. Then, one could induce  rhythm electrically and
pharmacologically in a mouse model of psychosis (e.g.,
phencyclidine-induced hyperlocomotion) and deter-
mine the direct effects of induction or inhibition of 
rhythm on psychotic behaviors and whether the two
types of stimulation have differential effects on those
behaviors. In this way, one could truly identify differ-
ent signaling components that are necessary and/or
sufficient for generating  rhythm and improving psy-
chotic symptoms.
The TRPV1 approach provides another opportunity
for combining two techniques. Early studies used photo-
caged capsaicin to provide high spatiotemporal resolu-
tion (Zemelman et al., 2003; Lima and Miesenböck,
CELL-TYPE CONTROL OF SIGNALING 311
2005); several years later, Arenkiel et al. (2008) elicited
stereotypies with uncaged capsaicin. The stereotypies
occurred within 5 to 15 min after capsaicin infusion.
Using caged capsaicin in vivo would improve the tempo-
ral precision of this approach. Local infusion of capsaicin
is already invasive and technically more demanding
than peripheral drug administration, so adding photo-
stimulation to the experimental design should not be
prohibitively challenging.
C. Concluding Thoughts
Techniques for experimental manipulation of neuro-
nal signaling have improved phenomenally in the last
decade, and we now have the ability to directly alter
neuronal activity via several different mechanisms. Re-
searchers in other fields are taking similar approaches
to remotely modifying particular intracellular activities
such as calcium channel activity [via a MIST-like
dimerization approach (Yang et al., 2007)], kinase activ-
ity, and others. In a short time, researchers might be able
to remotely control the level and/or direction of activity of
many cellular proteins and functions. A DREADD-like re-
ceptor tyrosine kinase or a chimera of an opsin and a
receptor tyrosine kinase would be a nice addition to the
receptor toolbox.
We have described the translational potential of these
techniques. In particular, the retina is well suited to
clinical applications because the vitreous humor is eas-
ily accessible for viral injections, and viral gene therapy
for blindness has already shown success in clinical tri-
als. The main obstacle to translation of these techniques
to human therapy, however, remains the ability to
safely, reliably, and stably express an exogenous protein
in human tissue. Until such gene therapy is routine, it
will be difficult to fully realize the clinical potential of
these techniques. Nonetheless, currently they are excel-
lent tools for improving our understanding of the biolog-
ical basis of behavior.
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